オプション
〜
検索条件をクリア

書籍詳細

未契約
書籍名 癌の薬剤耐性とその克服 ―基礎と臨床―
出版社 宇宙堂八木書店
発行日 2001-02-15
著者
  • 大沼尚夫(編集)
  • 竹村譲(編集)
ISBN 4771950539
ページ数 407
版刷巻号 第１版第１刷
分野
閲覧制限 未契約

本書は、抗癌剤耐性のメカニズムに関して最新の知見を紹介するとともに、臨床的にも注目に値する薬剤耐性克服へのアプローチを、専門の研究者のみならず、広く癌の臨床に携わる医師、抗癌剤耐性に興味を持つ初学者、学生にも理解し易く解説することをめざして企画された。(序文より)

目次

  • 表紙
    閲覧
  • 序文
    閲覧
  • 執筆者一覧
    閲覧
  • 目次
    閲覧
  • I. 抗癌剤の種類と作用機序
    P.1閲覧
  • II. 癌の薬剤耐性実験系
    閲覧
    • 1. In vitro実験系
    • 2. In vivo実験系
    • 3. 癌細胞の抗癌剤感受性試験
  • III. 癌の薬剤耐性機構
    閲覧
    • 1. 抗癌剤耐性形質の細胞薬理学的・生化学的機構
    • 2. 薬剤耐性の分子薬理機構
    • 3. 多剤耐性形質とその分子薬理機構
      • (1) 多剤耐性序論
      • (2) MDRI遺伝子を介した多剤耐性
      • (3) MRP, LRP, その他
      • (4) トポイソメラーゼIIを介した多剤耐性
      • (5) DNA修復機構と抗癌剤感受性
      • (6) p53の変異による多剤耐性, チュブリン蛋白変異による多剤耐性, その他
    • 4. アポトーシスと抗癌剤耐性
    • 5. 生体内薬物動態に関係した薬剤耐性
  • IV. 抗癌剤耐性克服へのアプローチ
    閲覧
    • 1. サイトカイン / 造血幹細胞移植を用いた強化化学療法
    • 2. 多剤併用療法
    • 3. 抗腫瘍効果増強剤の使用による耐性克服
    • 4. 薬剤耐性癌に対する免疫療法
    • 5. MDRモジュレーターによる多剤耐性克服
    • 6. 分子レベルでの薬剤耐性克服の試み
  • V. 各薬剤に特異的な耐性機構とその克服
    閲覧
    • 1. 葉酸代謝拮抗剤
    • 2. フッ化ピリミジン系薬剤およびプリン代謝拮抗剤
    • 3. Cytosine arabinosideとその誘導体
    • 4. アルキル化剤
    • 5. プラチナ化合物
    • 6. ブレオマイシン, ペプロマイシン
    • 7. アンソラサイクリン系抗腫瘍剤
    • 8. マイトマイシン
    • 9. チュブリン阻害性抗腫瘍薬
    • 10. トポイソメラーゼ阻害剤
    • 11. レチノイン酸耐性
    • 12. ホルモン療法剤に対する耐性
  • VI. 薬剤耐性形質の臨床的な検出検査法
    閲覧
    • 1. P-糖蛋白 / MDR1検出検査
    • 2. その他の薬剤耐性の遺伝子診断
    • 3. フローサイトメトリーの耐性診断への応用
  • VII. 癌の薬剤耐性機序の研究, 耐性克服の方法開発の今後の展望
    P.359閲覧
  • 索引
    閲覧
  • 奥付
    閲覧

参考文献

I. 抗癌剤の種類と作用機序

P.2 掲載の参考文献

  • 1) Luria SE, Delbruck M. Mutations in bacteria from virus sensitivity to virus resistance. Genetics. 1943; 28:491-511.
    pubmed
  • 3) Demerec M. Origin of bacterial resistance to antibiotics. J Bact. 1948; 56:63-74.
    pubmed
  • 5) Biesele JJ, Biedler JL Hutchison DJ. The chromosomal status of drug-resistant sublines of mouse leukemia L1210.In Genetics and Cancer, Austin, University of Texas press, 1959, pp. 2953-07.
  • 8) Bach MK Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to 1-bD-arabino-furanosylcytosine (cytarabine) hydrochloride. Cancer Res. 1969; 29:1881-5.
  • 9) Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep. 1979; 63:1727-33.
  • 14) Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981; 41:1967-72.
    pubmed
  • 16) Herzog CE, Tsokos M, Bates SE, Fojo AT. Increasedmdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem. 1993; 268:294652.
  • 17) Brangi M, Utman T, Ciotti M, et al. Camptothecin resistance:role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999; 59:593946.
  • 18) Childs S, Yeh RL, Hui D, ling V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glyco-protein. Cancer Res. 1998; 58:4160-7.
  • 19) Awasthi S, Shinghal SS, Cheng J, et al. RLIP76 is a glutathione-conjugate and drug transporter. Proc Am Assoc Cancer Res. 2000; 41:803.

P.12 掲載の参考文献

  • 3) 古江 尚, 太田和雄, 田口鐵男, 他編著. 癌化学療法の基礎と臨床. 東京:蟹書房, 1977, pp. 82-174.
  • 4) 小川一誠, 編. 抗癌剤の選び方と使い方改訂第2版. 東京:南江堂, 1999, pp. 29-43.
  • 5) 近田千尋. Procarbazine. 癌の化学療法剤. 斉藤達雄, 監修, 東京:クリニックマガジン, 1977, pp. 169-80.
  • 8) 相羽恵介, 大澤 浩, 小川一誠LV/5FU Biochemical modulation の基礎と臨床. 金丸竜之介, 他編, 東京:医学書院, 1995, pp. 29-40.
  • 9) 白坂哲彦, 島本勇司, 加藤利幸, 他. Biochemical modulation を応用した腫瘍選択毒性の高い新規5-Fluorouracil系抗癌剤Slの基礎的研究.癌と化学療法. 1998; 25:371-84.
  • 10) 小川一誠. Cytarabine (キロサイド). 癌の化学療法剤. 斉藤達雄, 監修, 東京:クリニックマガジン, 1977, pp. 2581.
  • 11) 浦部晶夫, 溝口秀昭, 正岡徹, 他. 骨髄増殖性疾患に対する Hydroxyurea の臨床的検討医学と薬学. 1990; 24:1571-85.
  • 14) O'Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda (capecitabine) VS CMF as first line chemotherapy of breast cancer in women aged ≧55 years. Proc Arn Soc Clin Oncol. 1998:17:103a.
  • 17) 大西一功, 大野竜三. Fludarabine. 血液・腫瘍科. 1998; 35:412-6.
  • 18) 伊勢 泰. Actiomycin D. 癌の化学療法斉. 斉藤達雄, 監修, 東京:クリニックマガジン, 1977, pp97-103.
  • 19) Hata T, Sano R, Sugawara R, et al. Mitomycin, a new antibiotic from streptomyces I. J Antibiot Ser A 1956; 9:141-6.
  • 21) Di Marco A Gaetani M, Dorigotti L, et al. Daunomycin:A new antibiotic with antitumor activity. Cancer Chemo Rept. 1964; 38:31-8.
  • 22) Di Marco A, Gaetani M, Scarpinato B. Adriamycin (NSC-123, 127), a new antibiotic with antitumor activity. Cancer Chemo Rept. 1969; 53:33-7.
  • 23) 小川一誠 Idarubicin. 血液・腫瘍科.1992; 24:441-5.
  • 24) Johnson IS, Armstrong JG, Goman M, et al. The vinka Alkaloid:Anew class of oncolytic agents. Cancer Res. 1963; 23:1390-427.
  • 25) 小川一誠, 相羽恵介, 堀越昇, 他. 進行悪性腫瘍における新しいポドフィロトキシンVP16-213の phase II study. 癌と化学療法1981; 8:1892-6.
  • 26) 古江 尚. 塩酸イリノテカン. 癌と化学療法 1994; 21:709-17.
    Medical*Online
  • 27) 小川一誠タキソール (Taxol). 最新医学. 1991; 46:2630.
  • 28) 山田一正. Lasparaginase (ロイナーゼ). 癌の化学療法剤. 斉藤達雄, 監修, 東京:クリニックマガジン, 1977, pp. 163-8.
  • 29) Bono VH, Studies on the mechanism of action of DTIC (NSC-45388). Cancer Treat Rep. 1976; 60:141-8.
    pubmed
  • 30) 古江 尚. MST-16 (ソブゾキサン). 血液・腫瘍科. 1992; 24:433-40.
  • 31) 山田 治, 畠 清彦, 谷本光音, 他. 急性前骨髄球性白血病に対するトレチノン (Ro01-5488) の分化誘導療法. 癌と化学療法. 1994; 21:1981-9.

P.21 掲載の参考文献

  • 2) Ruddon RW. Biochemistry of Cancer. In:Bast RC Jr, Kufe DW, Pollack RE, et al. eds., Cancer Medicine, 5th Edition, B. C. Decker, Hamilton, Ontario, Canada, 2000, pp. 108-20.
  • 4) Khlief SN. Curt GA Animal models in developmental therapuetics. In:Bast RC Jr, Kufe DW, Pollack RE, et al. eds. Cancer Medicine, 5th Edition, Hamilton, Ontario, Canada:B. C Decker, 2000, pp. 573-84.
  • 6) Pelletier H, Millot JM, Chauffert B, et al. Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines:alteration of drug-passive diffusion. Cancer Res. 1990; 50:662-31.
  • 7) 河本圭司, 井上勝一, 中内啓光, 他編. 応用サイトメトリー, 東京:医学書院, 2000, pp. 369.
  • 8) 中島 収, 井上勝一, 小林邦彦. ヒト肺癌培養細胞株のシスプラチン, カルボプラチン, 254-Sの細胞内取り込み量の検討肺癌. 1994; 34:313-9.
  • 9) Sandberg AA, ed. The Chromosomes in Human Cancer and Leukemia, 2nd Ed, New York:Elsevier, 1990, pp, 1315.
  • 11) Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms:aproposal from the lnternational Lymphoma Study Group. Blood. 1994; 84:1361-92.
  • 13) Nanauska A-R, von Hoff DD. In vitro and in vivo predictive Tests. In:Bast RC Jr, Kufe DW, Pollack RE, et al. eds., Can-cer Medicine, 5th Edition, Hamilton, Ontario, Canada:B. C. Decker, 2000, pp. 5858.
  • 15) Kimmig A Gekeler V, Neumann M, et al. Susceptibility of multidrug-resistant human leukemia cell lines to human in-terleukin 2-activated killer cells. Cancer Res. 1990; 50:6793-9.
  • 17) Gruber A, I arsson R, Nygren P, et al. A non-P-glycoprotein-mediated mechanism of vincristine transport which is affect-ed by resistance modifiers and present in chemosensitive cells. Leukemia. 1994; 8:9859.
  • 18) Tsuruo T, Iida-Saito H, Kawabata H, et al. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and isolated clones. Jpn J Cancer Res. 1986; 77:682-92.
    pubmed
  • 21) Hall KS, Endressen L, Huitfeldt HS, et al. Induction of in vitro resistance to 4:-epidoxorubicin and cis-dichlorodiamineplatinum in hepatoma cells. Anticancer Res. 1991; 11:817-23.
  • 24) Sugimoto Y, Tsukahara S, Oh-Hara T, et al. Elevated ex-pression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 1990; 50:7962-5.
  • 27) Teicher BA, Holden SA Kelley MJ, et al. Characterization of ahuman squamous carcinoma cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res. 1987; 47:388-93.
  • 30) Cheng RM, Zhu DH, Ye XZ, et al. Establishment and some biological characteristics of human hepatocellular carcinoma cell line Bel7402.Acta Biol Exp Sin. 1978; 11:37-45.
  • 33) Datta R, Manome Y, Taneja N, et al. Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 1995; 6:363-70.
    pubmed
  • 37) Scwarz MA Lazo JS, Yalowich JC, et al. Cytoplasmic metal-lothionein overexpression protects NIH3T3 cells from tert-butyl hydroperoxide toxicity. J Biol Chem. 1994; 21:15238-43.
  • 39) Morrow CS, Cowan KII. Drug resistance and its clinical circumvention. In:Bast RC Jr, Kufe DW, Pollack RE, et al. eds., Cancer Medicine, 5th Edition, Hamilton, Ontario, Can-ada:B. C. Decker, 2000, pp. 539-55.
  • 41) Weisenthal LM, Marsden JA, Dill PL, et al. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 1983; 43:749-57.
    pubmed
  • 43) Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48:589-601.
    pubmed
  • 44) Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay fbr cell growth and dnlg sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988; 48:4827-33.
  • 46) Berridge MV, Tan AS. Characterization of the cellular reduction of 3 (4, 5dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTr):subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTr reduction. Arch Biochem Biophys. 1993; 303:474-82.
  • 48) Belloti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996; 2:1843-9.
  • 55) Furukawa T, Kubota T, Hoffman RM. Clinical application of the histoculture drug response assay. Clin Cancer Res. 1995; 1:305-11.
    pubmed
  • 56) Ohie S, Udagawa Y, Kozu A et al. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxombicin and cyclophosphamide. Anticancer Res. 2000; 20:2049-54.
    pubmed
  • 59) Leveille-Webster CR, Ahas IA. Establishment and serial quantification of intrahepat, ic xenografts of human hepato-cellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance. Clin Cancer Res. 1996; 2:695-706.
  • 62) Bellet RE, Danna V, Mastrangelo MJ, et al. Evaluation of a "nucle" mouse-human hlmor panel as a predictive secondary screen for cancer chemotherapeutic agents. J Natl Cancer Inst. 1979; 63:11858.
  • 64) Nederman T, Norling B, Glimelius B, et al. Demonstration of an extracellular matrix in multicellular tumor spheroids. Cancer Res. 1984; 44:3090-7.
    pubmed
  • 65) Sutherland RM, Durand RE. Hypoxic cells in an in vitro tumor model. Int J Radiat Biol. 1973; 23:23546.
  • 67) Freyer JP, Sutherland RM. Selective dissociation and characterization of cells from different regions of multicell tumor spheroids. Cancer Res. 1980; 40:395-65.
  • 68) Allison DC, Yuhas JM, Ridolpho PF, et al. Cytophotometric measurement of the cellular DNA content of [3H] thymidine-1abelled spheroids. Demonstration that some non-labelled cells have S and G2 DNA content. Cell Tissue Kinet. 1983; 16:237-46.
  • 74) Iwasaki K Kikuchi H, Miyatake S, et al. Infiltrative and cytolytic activities of lymphokine-activated killer cells against a human glioma spherold model. Cancer Res. 1990; 50:2429-36.
    pubmed
  • 78) Garrido C, Ottavi P, Fromentin A, et al. HSP27 as a mediator of confluence-dependent resistance to cell death in (hlced by anticancer drugs. Cancer Res. 1997; 57:2661-7.
    pubmed

P.30 掲載の参考文献

  • 5) 三枝理恵子, 阿部良行, 浦野浩司, 他. ヒト腫瘍移植動物としてのSCIDマウスの有用性-各種臓器別腫瘍の生着率について-. 第40回実験動物学会総会抄録集.1993; 140.
  • 10) Maruo K Ueyama Y, Inaba M, et al. Responsiveness of subcutaneous human glioma xenografts to various anti-cancer agents. Anticancer Res. 1990; 10:209-12.
    pubmed
  • 15) 前川昭彦. 実験動物における自然発生腫瘍. 腫瘍組織病理アトラス-実験動物の自然発生腫瘍. 西塚泰章, 高山昭三, 伊 東信行, 他編. 東京:文光堂, 1985, pp. 1-5.
  • 16) Povlsen CO, Jacobson GK Chemotherapy of a human malig-nant melanoma transplanted in the nude mouse. Cancer Res. 1975; 35:2790-6.
  • 18) 吉田富三. 吉田肉腫-癌化学療法の基礎的研究. 東京:寧楽書房, 1949, pp, 100.
  • 19) 市村宏子. ラット腹水肝癌を用いた癌化学療法のスクリーニング. 癌と化学療法 1975; 2:605-10.
  • 20) Sugiura K, Schmid FA, Schmid MM, et al. Effect of compounds on a spectrum of tumors. Cancer Chemother Rep. 1972; 3:231-308.
    pubmed
  • 25) Thompson J, George EO, Poquette CA et al. Synergy of topotecanin combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999; 5:3617-31.
    pubmed
  • 27) Hoffman RM. Orthotopic metastatic mouse models for anti-cancer drug discovery and evaluation:abridge to the clinic. Invest New Drugs. 1999; 17:34359.
  • 33) Nakamura M, Oshika Y, Abe Y, et al. Gene expression of granulocyte colony-stimulating factor (G-CSF) in non-small cell lung cancer. Anticancer Res. 1997; 17:573-6.
    pubmed
  • 36) Kijima H, Abe Y, Yamazaki H, et al. Stability of RAS oncogene mutation in the human tumor xenografts through serial passages. Anticancer Res. 1994; 14:2583-8.
    pubmed
  • 37) Tsugu A, Kijima H, Yamazaki H, et al. Localization of aberrant messenger RNA of epidermal growth factor receptor (EGFR) in malignant glioma. Anticancer Res. 1997; 17:222532.
  • 40) Abe Y, Nakamura M, Saegusa R, et al. In vivo acquired drug resistance and multidrug resistance genc (MZ) Rl) expres-sion in the KB carcinoma cell line xenotransplanted in nude mice. Tokai J Exp Clin Med. 1993; 18:99-106.
  • 42) Abe Y, Yamazaki H, Oshika Y, et al. Advantage of in vivo chemosensitivity assay to detect vincristine-resistance in a human epidermoid carcinoma xenograft. Anticancer Res. 1996; 16:729-34.
  • 45) Suto R, Abe Y, Nakamura M, et al. P-glycoprotein-mediated acquired multidrug resistance of human osteosarcoma xenografts in vivo. Int J Oncol. 1998; 12:287-91.
    pubmed
  • 47) 勝木元也. トランスジェニックマウスを用いた実験. 蛋白核酸酵素. 1995; 40:2001-7.
  • 48) 丸尾幸嗣. 腫瘍の移植方法. 野村達次, 櫻井欽夫, 稲葉実, 編. ヌードマウスと抗癌剤評価. 東京:蟹書房, 1991, p.200-9.
  • 50) Bogden AE, Kelton DE, Cobb WR, Esber HJ. A rapid screening method for testing chemotherapeutic agents against human tumor xenografts. In:Houchens DP, Ovvejera AA, eds. Proceedings of Symposium on the Use of Athymic (Nude) Mouse. NY:Gustav Fischer, 1978, p. 231-50.
  • 52) McLemore TL, Liu MC, Blacker PC, et al. Novel intrapulmonary model for orthotropic propagation of human lung cancers in athymic nude mice. Cancer Res. 1987; 47:5132-40.
  • 53) Gorelik E, Ovejera A, Shoemaker R. et al. Microencapsulated tumor assay:new short term assay for in vivo evaluation of the effects of anticancer drugs on human tumor cell lines. Cancer Res. 1987; 47:5739-47.
    pubmed
  • 54) Noso Y, Niimi K Nishiyama M, et al. Clinical studies on a new screening assay for anticancer agents using nude mice and isotopic evaluation. Cancer Res. 1987; 47:6418-22.
    pubmed
  • 56) Ueda K Clark DP, Chen C, et al. The human multidrug resistance (MDRI) gene. J Biol Chem. 1987; 262:5058.
  • 57) Chen C, Clark D, Ueda K, et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoprotein. J Biol Chem. 1990; 265:50614.
  • 61) Imanishi T, Abe Y, Suto R, et al. Expression of the human multidrug resistance gene (MDR1) and prognostic correla-tion in human osteogenic sarcoma. Tokai J Exp Clin Med. 1994; 19:3946.

P.39 掲載の参考文献

  • 2) Kondo T, Imamura T, Ichihashi S. In vitro test for sensitivity of tumor to carcinostatic agents. Gann. 1966; 57:113-21.
  • 8) Furukawa T, Kubota T, Hoffman RM. Clinical application of histoculture drug response assay. Clin Cancer Res. 1995; 1:30511.
  • 9) Kitaoka A Muraoka, Tanigawa N. Improvement of in vitro chemosensitivity assay for human solid tumors by application of a preculture using collagen matrix. Clin Cancer Res. 1997; 3:2959.
  • 10) Kubota T, Sasano N, Abe O, et al. The potential of the histoculture drug response assay to contribute to cancer patient survival. Clin Cancer Res. 1995; 1:1537-43.
    pubmed
  • 14) Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996; 56:892-8.
    pubmed
  • 16) Lenz H, Hayashi K Salonga D, et al. p53 Point mutation and thymidylate synthase messenger RNA levels in disseminated colorectal cancer:An analysis of response and survival. J Clin Oncol 1998; 4:1243-50.
  • 17) Abe S, Kubota T, Matsuzaki SW, et al. Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer che-motherapy for stage III non-scirrhous and scirrhous gastric cancers. Anticancer Res. 1999; 19:4581-6.
  • 22) Cortazar P, Gazdar AF, Woods E, et al. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res. 1997; 3:741-7.
    pubmed
  • 27) Baker FL, Spitzer G, Ajani JA, et al. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. Cancer Res. 1986; 46:126374.
  • 28) 出口隆, 根笹信一, 川本正吾, 他. 膀胱癌に対する動注治療の効果の予測因子の検討-ATP法による抗癌剤感受性試 験の有用性について-. 日泌誌. 1994; 85:152833.
  • 29) 一志公夫, 黒田 徹. 蛍光染色を用いた抗癌剤感受性試験. 日癌治誌1995; 30:168491.
  • 30) 高原哲也. Growth chamberを用いた抗癌剤感受性試験. 日外会誌1995; 96:5971.

P.49 掲載の参考文献

  • 2) Yarbro JW. The scientific basis of cancer chemotherapy. In:Peny MC, ed. The Chemotherapy Source Book. Baltimore MD:Wllliams & Wilkins, 1992, pp. 2-14.
  • 6) Ohnoshi T, Ohnuma T, Takahashi I, et al. Establishment of methotrexate-resistant human acute lymphoblastic leukemic cells in culture and effects of folate antagonists. Cancer Res. 1982; 42:165560.
  • 8) Ohnuma T, Lo RJ, Scanlon KJ, et al. Evolution of metho-trexate resistance of human acute lymphoblastic leukemia cells in vitro. Cancer Res. 1985; 45:181522.
  • 9) Sirotnak FM, Moccio DM, Goutas LJ, et al. Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate:resistant murine tumors to the lipophilic antifolate, metoprine. Cancer Res. 1982; 42:924-30.
  • 10) Goldenberg GJ, Vanstone CL, Israels LG, et al. Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and-resistant L5178Y lymphoblasts. Cancer Res. 1970; 30:2285-91.
    pubmed
  • 11) Redwood WR, Colvin M. Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res.1980; 40:1144-9.
    pubmed
  • 14) Pizzomo G, Mini E, Coronnello, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res. 1988; 48:214955.
  • 15) McCloskey DE, McGuire JJ, Russell CA, et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem. 1991; 266:6181-7.
    pubmed
  • 16) Li WW, Waltham M, Tong W, et al. Increased activity of γ-glutamyl hydrolase in human sarcoma cell lines:anovel mechanism of intrinsic resistance to methotrexate. In:Ayling JE, et al. eds. Chemistry and Biology of Pteridines and Folates (Adv Exp Med Biol 338). New York, NY:Plenum Press, 1993, pp. 635-8.
  • 17) Rhee MS, Wang Y, Nair MG, et al. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res. 1993; 53:2227-30.
  • 24) Grem JL. 5-Fluoropyhmidines. In:Chabner B.A. Longo DL, eds. Carlcer Chemotherapy and Biotherapy:Principles and Practice, 2nd ed. Philadelphia, PA:Lippincott-Raven, 1996, pp. 149-211.
  • 27) McComack JJ, Johns DG. Purine and purine nucleoside antimetabolites. In:Chabner BA, Collins JM eds. Cancer Chemotherapy:Principles & Practice. New York, NY:J. B. Lippincott, 1990, pp. 234-52.
  • 29) Robson CN, Lewis AD, Wolf CR, et al. Reduced levels of drug-induced DNA crosslinking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity. Cancer Res.1987; 47:6022-7.
    pubmed
  • 34) Hilton J. Role of aldehyde dehydrogenase in cyclophospha-mideresistant L1210 leukemia. Cancer Res. 1984; 44:515660.
  • 36) Schilsky RL. Antimetabolites 3.cytosine arabinoside. In:Perry MC ed. The Chemotherapy Source Book. Baltimore, MD:Williams & Wilkins, 1992, pp.308-9.
  • 37) Lee MH, Huang Y-M, Sartorelli AC. Nkaline phosphatase activities of 6-thiopurine sensitive and resistant sublines of sarcoma 180.Cancer Res. 1978; 38:2413-8.
    pubmed
  • 41) Scudiero DA, Meyer SA, Clatterbuck BE, et al. Sensitivity of human cell strains having different abilities to repair O6-methyl guanine in DNA to inactivation by alkylating agents including chloroethyl nitrosoureas. Cancer Res.1984; 44:2467-74.
    pubmed
  • 42) 西條長宏. シスプラチン耐性とその克服. Mebio. 1993; 7:806.
  • 43) Hughes EN, Engelsberg BN, Billings PC. Purification of nuclear proteins that bind to cisplatin-damaged DNA. J Biol Chem. 1992; 267:13520-7.
  • 46) Chu E, Allegra CJ. Antifblates. In:Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy:Principles and Practice, 2nd ed. Philadelphia, PA Lippincott-Raven, 1996, pp. 109-48.
  • 48) Berger SH, Jenh CH, Johnson LF, et al. Thymidylate synthase overproduction and gene amplication in fluorodeoxy-uridine-resistant human cells. Mol Phamacol. 1985; 28:461-7.
  • 49) Jackman AL, Alison DL, Calvert AH, et al. Increased thymidylate synthase in L1210 cells possessing acquired resistance to Nlo-propargyl-5, 8-dideazafolic acid (CB3717):development, characterization, and cross-resistance studies. Cancer Res. 1986; 46:2810-5.
  • 51) Srimatkandada S, Schweitzer BI, Moroson BA, et al. Amplification of a polymorphic dihydrofblate reductase gene ex-pressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this dnlg. J Biol Chem. 1989; 264:3524-8.
  • 54) Hinds M, Deisseroth K Mayes J, et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 1991; 51:472931.
  • 56) Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubuhn. J Biol Chem. 1991; 266:3987-94.
    pubmed
  • 63) Li WW, Lin JT, Tong WP, et al. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res. 1992; 52:1434-8.
    pubmed
  • 64) Li WW, Lin JT, Schweitzer BI, et al. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res. 1992; 52:390-13.
  • 65) Pizzomo G, Chang YM, McGuire JJ, Bertino JR. Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res. 1989; 49:5275-80.
  • 67) Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16.Cancer Res. 1988; 48:192-9.

P.59 掲載の参考文献

  • 1) Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem. 1968; 243:5007-17.
  • 2) Moscow JA, Gong M, He R, et al. Isolation of a gene encoding ahuman reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 1995; 55:37904.
  • 11) 植田和光:抗癌剤に対する膜輸送機構の変化を介した耐性 機構. 日本臨牀. 1997; 55:1024-9.
    Medical*Online
  • 13) 西尾和人, 中村 貴:抗癌剤感受性, 耐性の分子機構. 肺癌の臨床. 1999; 2:457-63.
  • 16) Moran RG. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites:an over-view. Seminars in Oncol. 1999; 26:24-32.
  • 17) McGuire JJ, Russell CA. Folyepolyglutamate synthetase expression in antifolate-sensitive and resistant human cell lenes. Oncol Res. 1998; 10:193-200.
  • 20) Flasshove M, Strumberg D, Ayscue L, et al. Structural analy-sis of the deoxycytidine knase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia. 1994; 8:780-5.
  • 22) Markinson AM, Siegel D, Forrest GL et al. Elevated DT diaphorase activity and messenger RNA content in human non-small cell lung carcinoma:relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res. 1992; 52:4752-7.
  • 23) Mikami K Naito M, Tomida A, et al. DTdiaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res. 1996; 56:28236.
  • 25) Kondo Y, Woo ES, Michalska AE, et al. Metallothionein null cells have increased sensitivity to andcancer drugs. Cancer Res, 1995; 55:2021-3,
  • 26) Yang YY, Robbins PD, Lazo JS. Differential transactivation of human metallothionein-II α in cisplatin-resistant and-sensitive cells. Oncology Res. 1998; 10:859.
  • 29) Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase; regulation and importance in response to alkylating carcino-genic and therapeutic agents. Cancer Res. 1990; 50:6119-29.
  • 31) Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltrans-ferase and survival of brai tumor patients treated with carmustine. Cancer Res. 1996; 56:783-8.
  • 40) Schimke RT. Gene amplification, drug resistance, and cancer. Cancer Res. 1984; 44:173542.
  • 43) Berger SH, Jenh C-H, Jonson LF, Berger FG. Thymidylate synthase overproduction and gene amplification in fluorode-oxyuridine-resistant human cells. Molecular Pharmacology. 1985; 28:461-7,
  • 44) Taniguchi K Kohno K Kawanami K et al. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res. 1996; 56:2348-54.
    pubmed
  • 46) Takano H, Kohno K, Ono M, et al. Increased phosphorylation of DNA topoisomerase II in Etoposide-resistant mutants of human cancer KB cells. Cancer Res. 1991; 51:3951-7.
    pubmed
  • 47) Kubo T, Kohno K Ohga T, et al. DNA topoisomerase II α gene expression under transcriptional control in Etoposide/Teniposide-resistant human cancer cells. Cancer Res. 1995; 55:3860-4.
  • 48) Wang Q, Zambetti GT, Suttle DP. Inhibition of DNA topo-isomerase II α gene expression by the p53 tumor suppressor. Mol Cell Biol. 1997; 17:389-98.
  • 53) Komatani H, Morita M, Sakaizumi N, et al. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase L Cancer Res. 1997; 59:2701-8.
  • 56) Mareya SM, Sorrentino BP, Blakley RL. Protection of CCRF-CEM human lymphoid cells from antifblates by retroviral gene transfer of variants of murine dihydrofolate reductase. Cancer Gene Therapy. 1998; 5:225-53.
    pubmed
  • 58) Karnik PS, Kulkarni S, Liu XP, et al. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994; 54:349-53.
    pubmed
  • 63) Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clinical Cancer Res. 1996; 2:277-85.

P.62 掲載の参考文献

P.72 掲載の参考文献

  • 2) Inaba M, Kobayashi H, Sakurai Y, et al. Active efnux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979; 39:2200-3.
    pubmed
  • 5) Ueda K Clark DP, Chen C-j, et al. The human multidmg resistance (mdr1) gene. J Biol Chem. 1987; 262:5058.
  • 7) Folo A Akiyama S, Gottesman MM, et al. Reduced drug accumulation in multiply drug-resistant human KB carcino-ma cell lines. Cancer Res. 1985; 45:3002-7.
  • 15) Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992; 263:840-5.
  • 23) Tatsuta T, Naito M, Oh-hara T, et al. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992; 267:2038391.

P.78 掲載の参考文献

  • 3) Chen C, Clark D, Ueda K, et al. Genomic organization of the human multidrug P3 resistance (MDR1) gene and origin of P-glycoprotein. J Biol Chem.1990; 265:506-14.
  • 4) Chen H, Bamberger U, Heckel A, et al. BIBW 22, dipyrida-mole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res. 1993; 53:1974-7.
  • 5) Smith CD, Carmeli S, Moore RE, Patterson GML. Scyto-phycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993; 53:1343-7.
  • 7) Versantvoort CHM, Broxterman HJ, Pinedo HM, et al. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 1992; 52:17-23.
  • 8) Zaman GJR, Versantvoort CHM, Smith JJM, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resis-tance lung cancer cell lines. Cancer Res. 1993; 53:1747-50.
  • 9) scheper RJ, Broxterman HJ, Scheffer GL, et al. Overex-pression of a M (r) 110, 000 vesicular protein in non-P-glyco-protein-mediated multidrug resistance. Cancer Res. 1993; 53:1475-9.
  • 13) Grant CE, Valdimarsson G, Hpfner DR, et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994; 54:357-61.
  • 14) Cole SPC, Sparks K-E, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994; 54:5902-10.
  • 17) Oshika Y, Nakamura M, Tokunaga T, et al. Multidrug resistance-associated protein (MRP) and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol. 1998; 11:1059-63.
    pubmed
  • 26) Bordow SB, Harber M, Madfiglo J, et al. Expression of the multidrug resistance associated protein (MRP) gene corre-lates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994; 54:5036-40.
  • 28) Dingemans AMC, Witlox AM, Stallaert RALM, et al. Ex-pression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res. 1999; 5:2048-58.
  • 31) Flens MJ, Izquierdo MA, Scheffer GL, et al. Immunohistochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994; 54:4557-63.
    pubmed
  • 35) Brock I, Hipfner DR, Nielsen BS, et al. Sequential co-expression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer lines. Cancer Res. 1995; 55:45962.
  • 39) Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exon 2 through 11 and lmmunohistochemical staining are required to detect all known p53 alteration in human malignancies. Oncogene. 1996; 13:1971-81.
  • 40) Wang QT, Beck WT. Transcriptional suppression of multi-drug resistance-associated protein (MRP) gene expression by wild-type p53.Cancer Res. 1998; 58:5762-9.
  • 41) Nakamura M, Abe Y, Katoh Y, et al. A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration. Anticancer Res. 2000; 20:1921-6.
    pubmed
  • 44) Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996; 148:877-87.
    pubmed
  • 47) Slovak ML, Ho JP, Bhardwaj G, et al. Localization of novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 1993; 53:3221-5.
    pubmed
  • 48) Schedendorf D, Makki A, Stahr C, et al. Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 1995; 147:154552.
  • 54) Boesch D, Gaverriaux C, Jachez B, et al. In vivo circumvention of p-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.Cancer Res. 1991; 51:4226-33.
  • 55) Kadamu S, Maus M, Podding J, et al. Reversal of multidrug resistance by two novel indole derivatives. Cancer Res. 1992; 52:4735-40.
  • 61) Allikmets R, Schriml LM, Hutchinson A et al. A human placenta-specfic ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998; 58:5337-9.
  • 63) Childs S, Yeh RL, Hui D, Ling V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res. 1998; 58:4160-7.
    pubmed

P.83 掲載の参考文献

  • 1) Danks MK, Yalowich JC, Beck W. Atypical multiple drugs resistance in human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 1987; 47:1297-301.
    pubmed
  • 4) Ueda K Clark DP, Chen CJ, et al. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem. 1987; 262:505-8.
    pubmed
  • 8) 安藤俊夫. DNAトポイソメラーゼの生物機能. 癌と化学療法 1991; 18:1543-9.
    Medical*Online
  • 9) Hinds M, Deisseroth K Mayer J, et al. Identification of a point mutation In the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 1991; 51:4729-31.
  • 12) Gieseler F, Glasmacher A, Wilms K, et al. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epopodophyllotoxines. Leukemia. 1996; 10:1177-80.
    pubmed
  • 13) Woessner RD, Mattern MR, Mirabelli CK et al. Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisornerases II in NIH-3T3 cell. Cell Growth and Differ. 1991; 2:209-14.
  • 16) Khelifa T, Casabianca-Pignede MR, Rene B, et al. Expression of topoisomerases II alpha and beta in Chinese hamster lung cells resistant to topoisomerase II inhibitors. Mol Pharmacol. 1994; 46:323-8.
    pubmed
  • 17) Drake FH, Hofmann GA, Mong SM, et al. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res. 1989; 49:2578-83.
    pubmed

P.95 掲載の参考文献

  • 7) Aburatani H, Hippo Y, Ishida T, et al. Cloning and characterization of mammalian 8-hydroxyguanine-specific DNA glycosylase/apurinic, apyrimidiniclyase, a functional mutM homologue. Cancer Res. 1997; 57:2151-6.
  • 10) Chakravarti D, Ibeanu GC, Tano K, Mitra S. Cloning and expression in Escherichia coli of a human cDNA encoding the DNA repair protein N-methylpurine-DNA glycosylase. J Biol Chem. 1991; 266:15710-5.
    pubmed
  • 25) Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res. 1995; 55:2304-9.
    pubmed
  • 30) Kelland LR, Mistry P, Abel G, et al. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res. 1992; 52:1710-6.
  • 31) Ewig RA, Kohn KW. DNA damage and repair in mouse leukemia L1210 cells treated with nitrogen mustard, 1, 3-bis (2-chloroethyl)-1-nitrosourea, and other nitrosoureas. Cancer Res. 1977; 37:2114-22.
    pubmed
  • 32) Wu ZN, Chan CL, Eastman A, Bresnick E. Expression of human O6-methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents. Cancer Res. 1992; 52:32-5.
  • 37) Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998; 4:1-6.
    pubmed
  • 38) Pan SS, Yu F, Hipsher C. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells. Mol Pharmacol. 1993; 43:870-7.
    pubmed
  • 39) Warren AJ, Maccubbin AE, Hamilton JW. Detection of mitomycin C-DNA adducts in vivo by 32P-postlabeling:time course for formation and removal of adducts and biochemical modulation. Cancer Res. 1998; 58:453-61.
    pubmed
  • 41) Johnson SW, Laub PB, Beesley JS, et al. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 1997; 57:850-6.
    pubmed
  • 43) Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of ciaplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 1999; 59:3968-71.
  • 49) Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996; 56:4881-6.
    pubmed
  • 50) Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in DNA mismatch repair deficient cells. Clin Cancer Res. 1997; 3:1763-7.
    pubmed
  • 52) Frit P, Canitrot Y, Muller C, et al. Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum (II):Mol. Phamacol. 1999; 56:141-6.
  • 56) Will CL, Dolnick BJ. 5-Fluorouracil augmentation of dihydrofolate reductase gene transcripts containing intervening sequences in methotrexate-resistant KB cells. Mol Pharmacol. 1986; 29:643-8.
    pubmed
  • 57) Doong SL, Dolnick BJ. 5-Fluorouracil substitution alters pre-mRNA splicing in vitro. J Biol Chem. 1988; 263:4467-73.
    pubmed
  • 58) Warner HR, Rockstroh PA. Incorporation and excision of 5-fluorouracil from deoxyribonucleic acids in Escherichia coli. J Bacteriol. 1980; 141:680-6.
    pubmed
  • 59) Ingraham HA, Tseng BY, Gourian M, et al. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharmacol. 1982; 21:211-6.
  • 65) Sant ME, Lyons SD, Phillips L, Christopherson RI. Antifolates induce inhibition of amido phosphoribosyltransferase in leukemis cells. J Biol Chem. 1992; 267:11038-45.

P.103 掲載の参考文献

  • 1) 佐谷秀行, 編著. p53癌抑制の分子メカニズムと臨床応用. 細胞工学別冊, 東京:秀潤社, 1998.
  • 5) Ju JF, Banerjee D, Lenz HJ, et al. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res. 1998; 4:1315-22.
    pubmed
  • 6) Song K, Li Z, Seth P, et al. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol Res. 1997; 9:6039.
  • 9) Vasey PA, Jones NA, Jenkins S, et al. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol. 1996; 50:1536-40.
    pubmed
  • 11) Zastawny RL, Salvino R, Chen J, et al. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Onco-gene. 1993; 8:1529-35.
  • 12) Nguyen KT, Liu B, Ueda K et al. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res. 1994; 6:71-7.
    pubmed
  • 21) Galimberti S, Marchetti A, Buttitta F, et al. Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res. 1998; 18:2973-6.
    pubmed
  • 23) Preudhomme C, Lepelley P, Vachee A, et al. Relationship between p53 gene mutations and multidrug resistance (mdr 1) gene expression in myelodysplastic syndromes. Leukemia. 1993; 7:1888-90.
  • 27) Tada M, Matsumoto R, Iggo RD, et al. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 1998; 58:1793-7.
    pubmed
  • 29) Gan Y, Wientjes MG, Schuller DE, Au JL. Phamacodynamics of taxol in human head and neck tumors. Cancer Res. 1996; 56:2086-93.
  • 31) Moreira LF, Naomoto Y, Hamada M, et al. Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy. Anticancer Res. 1995; 15:639-44.
    pubmed
  • 33) Rosell R, Gonzalez Larriba JL, Alberola V, et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer:links between p53 and K-ras gene status and chemosensitivity. Semin Oncol. 1995; 22:12-8.
  • 34) Oshika Y, Nakamura M, Tokunaga T, et al. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol. 1998; 11:1059-63.
    pubmed
  • 38) Chevillard S, Lebeau J, Pouillart P, et al. Biological and clinical significance of concurrent p53 gene alterations, MDRI gene expression, and Sphase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res. 1997; 3:2471-8.
    pubmed
  • 44) Gan Y, Wientjes MG, Badalament RA, Au JL. Pharmacodynamics of doxorubicin in human bladder tumors. Clin Cancer Res. 1996; 2:1275-83.
    pubmed
  • 49) O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57:4285-300.
    pubmed
  • 53) Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p530f susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and-defective myeloid leukemic cells. Cell Growth Differ. 1993; 4:41-7.
    pubmed
  • 55) Kopnin BP, Stromskaya TP, Kondratov RV, et al. Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts. Oncol Res. 1995; 7:299-306.
  • 58) Kem MAHelmbach H, Artuc M, et al. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide:modulation of proto-oncogene expression. Anticancer Res. 1997; 17:4359-70.
    pubmed
  • 60) Tanaka H, Arakawa H, Yamaguchi T, et al. A ribunucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000; 404:42-9.

P.116 掲載の参考文献

  • 2) Inoue S. Cancer therapy and apoptosis. Jpn J Cancer Chemother. 1997; 24 (Suppl 1):102-14.
  • 8) Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis:P53-dependent and independent pathways. Oncogene. 1995; 11:199-210.
    pubmed
  • 11) Selvakumaran M, lin HK, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGFb1:a paradigm for distinct apoptotic pathways. Oncogene. 1994; 9:1791-8.
    pubmed
  • 12) Moberg KH, Tyndall WA, Hall DJ. Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line. J Cell Bioch. 1992; 49:208-15.
  • 14) Shimizu T, O'Connor PM, Kohn KW, et al. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell hne HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res. 1995; 55:228-31.
  • 21) Greenblatt MS, Bennett WP, Hollstein M, et al. Mutadons in the p53 tumor suppressor gene:clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54:4855-78.
    pubmed
  • 23) O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57:4285300.
  • 27) 井上勝一. Cyclin と細胞周期. 癌と化療. 1997; 24:909-18.
    Medical*Online
  • 29) Kerbel RS, St Croix B, Florenes VA et al. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell. 1996; 9:257-64.
    pubmed
  • 33) Chen ZH, Zhang H, Savarese TM. Gene deletion chemo-selectivity:codeletion of the genes for p161NK4, methylthio-adenosine phosphorylase, and the α-and β-interferones in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res. 1996; 56:108390.
  • 41) Herman JG, Jen J, Merlo A et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p151NK4B. Cancer Res. 1996; 56:722-7.
  • 56) Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992; 52:5407-11.
    pubmed
  • 66) Datta R, Manome Y, Tanela N, et al. Overexpression of Bcl-XI. by cytotoxic drug exposure confers resistance to ionizing radiation-induced intemucleosomal DNA fragmentation. Cell Growth Differ. 1995; 6:36370.
  • 71) Yamamoto M, Fukushima T, Hayashi S, et al. Correlation of the expression of nuclear factor-K B, tumor necrosis factor receptor type I (TNFR 1) and c-myc with the chnical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-α (TNF-SAM2). Anticancer Res. 2000; 20:611-8.
  • 72) Kim JY, Lee S, Hwangbo B, et al. NFκ-B activation is related to the resistance of lung cancer cells to TNF-α-induced apoptosis. Biochim Biophys Res Commun. 2000; 273:140-6.
  • 73) Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κ B path-way. J Biol Chem. 2000; 275:8027:31.
  • 84) Bodey B, Bodey B Jr, Siegel SE, et al. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling re-ceptor for immune escape of neoplastic cells? In Vivo. 1999; 13:357-73.
    pubmed
  • 86) Ferreira CG, Tolis C, Span SW, et al. Drug-induced apoptosis in lung cancer cells is not mediated by the Fa/Fasl (CD95/ APO1) signaling pathway. Clin Cancer Res. 2000; 6:203-12.
    pubmed
  • 87) Shinohara H, Yagita H, Ikawa Y, et al. Fas drives cell cycle progression in glioma cells via extracellular signal-regulate (l kinase activation. Cancer Res. 2000; 60:1760-72.

P.125 掲載の参考文献

  • 1) Goldie JH. Drug resistance. In:MC Perry Ed. The chemotherapy source book. 2nd ed., Baltimore, MD:Wilhams & Wilkins, 1996, pp. 63-100.
  • 2) Kaufman D, Chabner BA Clinical strategies for cancer treatment:the role of drugs. In:Chabner BA,Longo DL, eds. Cancer Chemotherapy and Biotherapy:Principles and Practice. 2nd ed., Philadelphia, PA Lippilcott-Raven, 1996, PP. 1-16.
  • 3) Gulhno PM. The internal milieu of tumors. Prog Exp Tumor Res. 1966; 8:1-25.
  • 5) Kobayashi K Jodrell DI, Ratain MJ. Pharmacodynamic-phamacokinetic relationships and therapeutic drug monitoring. Cancer Surv. 1993; 17:51-78.
  • 8) Collins JM. Clinical strategies for cancer treatment:the role of drugs. In:Chabner BA, Longo DL, eds. Cancer Chemo-therapy and Biotherapy:Principles and Practice. 2nd ed., Philadelphia, PA:Lippincott:Raven, 1996, pp. 17-29.
  • 11) Choi KE, Ratain MJ, W; illiams SF, et al. Plasma phamlacoki-netics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Cancer Res. 1989; 49:1318-21.
  • 12) Quijano RF, Ohnishi N, Umeda K, et al. Effect of atropine on gastrointestinal motility and the bioavailability of cyclo-sporine A in rats. Drug Metab Dispos. 1993; 21:141-3.
  • 19) Chu E, Allegra CJ. Antifolates. In:Chabner BA, Longo DL, eds, Cancer Chemotherapy and Biotherapy:Principles and Practice, 2nd ed., Philadelphia, PA:Lippincott-Raven Pub., 1996, pp. 109-48.
  • 23) Jain RK. Physiological resistance to the treatment of solid tumors. In:Teicher BA, ed. Drug Resistance in Oncology. New York, NY:Marcel Dekker, 1993, pp. 87-105.
  • 24) Dewhirst MN. Angiogenesis and blood flow in solid tumors. In:Teicher BA, ed. Dmg Resistance in Oncology. New York, NY:Marcel Dekker, 1993, pp. 324.
  • 25) Less JR, Skalak TC, Sevick EM, et al. Microvascular architecture in a mammary carcinoma:branching patterns and vessel dimensions. Cancer Res. 1991; 51:26573.
  • 27) Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep. 1983; 67:923-31.
    pubmed
  • 28) 富田章弘, 鶴尾 隆. ストレス応答と薬剤耐性. 最新医学. 1999; 54:2059-64.
  • 30) Durand RE. Chemosensitivity testing in V79 spheroids:drug delivery and cellular micro environment. J Natl Cancer Inst. 1986; 77:247-52.
  • 31) Tannock IF, Cowan DS, Shaikh H, et al. Penetration of anticancer drugs through solid tumors:afactor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res. 1999; 5:1583-6.
  • 32) Song CW, Lyons JC, Luo Y. Intra-and extracellular pH in solid tumors:influence on therapeutic response. In:Teicher BA, ed. Drug Resistance in Oncology. 2nd ed. New York, NY:Marcel Dekker, 1993, pp. 2581.
  • 34) Fergson PJ, Phillips JR, Selner M, et al. DUrerential activity of vincristine and vinblastine against cultured cells. Cancer Res. 1984; 44:3307-12.
  • 35) Ratain MJ. Pharmacology of cancer chemotherapy. In:DeVita VT Jr, et al., eds. Cancer:Principles & Practice of Oncology. Fifth ed. Philadelphia:Lippincott-Raven Pub, 1997, pp. 375-85.
  • 40) Donehower RC, Abeloff MD, Perry MC. Chemotherapy. In:A belloff MD, eds. Clinical Oncology. New York, NY:Chur-chill Livingstone, 1995, pp. 201-18.
  • 41) Brufman G, Biran S. Prognostic factors affecting treatment results with combination chemotherapy in metastatic breast cancer. Anticancer Res. 1986; 6:733-6.
    pubmed
  • 43) Green SK Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Ant-Cancer Drugs Des. 1999; 14:153-68.
  • 44) Heldin C-H, Claesson-Welsh L, Miyazono K et al. Growth regulatory proteins and their receptors. In:Bertino JR, ed. Encyclopedia of Cancer. San Diego, CA:Academic Press Inc, 1997, pp. 772-82.
  • 45) Dalton WS, Jove R Drug resistance in multiple myeloma:Approaches to circumvention. Sem Oncol. 1999; 26:23-7.
  • 48) Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Sem Hematol. 1999; 36:14-20.
  • 51) Kopreski MS. Interactions between chemotherapeutic drugs and biologic agents. In:Chabner BA, et al., eds. Cancer Chemotherapy and Biotherapy:Principles and Practice, 2nd ed. Philadelphia, PA:Lippincott-Raven Pub., 1996, pp. 765-85.
  • 54) Iaffaioli RV, Facchini G, Tortoriello A, et al. Modulation of chemosensitivity by alpha interferon in multiple myeloma and non-Hodgkin's lymphoma, J Exp Ther Oncol. 1996; 1:22630.

P.138 掲載の参考文献

  • 2) 尾山淳, 太田和雄, 浅野茂隆, 他. 非ポジキンリンパ腫に対する recombinant human G-CSF(rhGCSF注)の二重盲検交叉比較試験. 日癌治誌. 1990; 25:2533-48.
  • 3) DeVita V, Hubbard S, Longo DL, et al. The chemotherapy of Iymphomas:Looking back, moving forward-the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1987; 47:5810-24.
  • 4) DeVita VT. Principles of chemotherapy. In:DeVita VT, Hell-man S, Rosenberg SA (5th ed.). Cancer:Principles and Practice on Oncology. Philadelphia:JB Lippincott-Raven, 1997, pp333-47.
  • 7) Behrens BC, Hamilton TC, Masuda H, et al. Characteristics of cisdiamminedichloroplatinum (II):resistant human ovarian cancer cell line and its evaluation of platinum analogues. Cancer Res. 1987; 47:414-8.
  • 22) Henderson IC, Berry D, Demetri G, et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxombicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Arn Soc Clin Oncol. 1998; 17:101a.
  • 29) Goldie JH, Coldmann AJ, Cudauskas GA. Rationale for the use of altemating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982; 66:439-49.
  • 34) Bishop JF, Matthews Jp, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87:1710-7.
    pubmed
  • 35) Burchner T, Hiddelmann W, Womann B, et al. Double induction strategy for acute myeloid leukemia:the effect of high-dose cytarabine with mitoxarltrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine:ar andomized trial by the German AML Cooperative Group. Blood. 1999; 93:4116-24.
  • 36) Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997; 11:39749.
  • 42) 田口博國, 宍戸友明, 新津望, 他. 非ポジキンリンパ腫に対するG-CSF併用によるHigh Dose Biweekly CHOP療法. 癌と化学療法. 1998; 25:523-9.
  • 45) Ohtsu T, Wakita H, Igarashi T, et al. A phase I-II study of CHOP with or without prophylactic G-CSF for aggressive non-Hodgkin's lymphoma. Proc Am Soc Cnn Oncol. 1997; 16:20a.
  • 49) Blayney D, Horning SJ, Bartlett NL, et al. Filgrastim (r-metHuG-CSF) as an adjunct to CHOP chemotherapy in patients with intermediate or immunoblastic non-Hodgkin's lymphoma (NHL). Blood. 1992; 80 (suppl1):42a.
  • 51) 日本造血細胞移植学会. 平成10年度全国調査報告書. 1998.
  • 52) Mehta J, Powles R, Singhal S, et al. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant. 1995; 15:652-3.
    pubmed
  • 56) Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myelo-blastiques (GOELAM). Blood. 1997; 90:2978-86.
  • 58) Reifferss J, Stoppa AM, Attal M, et al. Allogeneic vs. autologous stem cell transplantation vs. chemotherapy in patients with acute myeloid leukemia in first remission:the BGMT 87 study. Leukemia. 1996; 10:187482.
  • 59) Fiere D, Sebbart C, Reiffers J, et al. Comparison of allogeneic transplantation, autologous transplantation, and chemotherapy as post induction treatment in adult acute lymphoblastic leukemia; long tem report of the French Group of Treatment of Adult ALL. Proc Am Soc Clin Oncol. 1998; 17:14a.
  • 67) Cunningham D, Paz-Ares L, Gore ME, et al. High-dose melphalan for multiple myeloma:long-term follow-up data. J Clin Oncol. 1994; 12:764-8.
  • 77) Shipp MA Abeloff MD, Antman KH, et al. Intenational consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas:report of the Jury. J Clin Oncol 999; 17:4239.
  • 79) Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgki's lymphoma. final analysis of the prospective LNH87-2 protocol. A GELA study. Blood 1999; 94 (suppl 1):610a.
  • 80) Milpied N, Deconninck E, Colombat Ph, et al. Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation compared to standard CHOP regimen:a randomize tial for adult patients with non IPI high-risk intermediate or high grade lymphomas (NHL). Blood. 1999; 94 (suppl 1):160a.
  • 83) Vose J, et al. Multivariate analysis of autotransplant for patients with aggressive non-Hodgkin's lymphoma failing primary induction therapy. Blood. 1997; 90 (suppl. 1):594a.
  • 85) Khouri I, Romaguera J, Kantarjian H, et al. Update of the HCVAD regimen followed by stem cell transplantation (SCT) in mantle cell lymphoma. Blood. 1999; 94 (supp 1):610a.
  • 88) Lotz Jp, Cure H, Janvier M, et al. High-dose chemother-apy (HD-CT) with hematopoietic stem cell transplantation (HSCT) for metastatic breast cancer (MBC):results of the French Protocol PEGASE 04.Proc Am Soc Clin Oncol. 1999; 18:43a.
  • 92) Hortobagyi GN, Buzdar AU, Champlin R, et al. Lack of efficacy of adjuvant highdose (hd) tandem combination chemotherapy (CT) fbr high-risk primary breast cancer (HRPBC)-a randomized trial. Proc Am Soc Clin Oncol. 1998; 17:123a.
  • 94) Peters W, Rosner G, Vredenburgh J, et al. A prospective randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving 100r more axillary lymph nodes (LN):preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13.Proc Am Soc Clin Oncol 1999; 18:1a.
  • 95) The Scandinavian Breast Cancer Study Group. Results from a randomized adjuvant breast cancer study with high-dose chemotherapy with CTC supported by autologous marrow stem cells versus dose escalated tailored FEC therapy. Proc Am Soc Clin Oncol. 1999; 18:2a.
  • 99) Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyo-sarcoma. J Clin Oncol 1999; 17:2796-2803.

P.150 掲載の参考文献

  • 1) Steel GG. Growth rate of tumours. In:Growth kinetics of tumours, Oxford:Clarendon Press. 1977, pp. 5-52.
  • 2) Schabel FM. The use of tumor growth kinetics in planning "curative"chemotherapy of advanced solid tumors. Cancer Res. 1969; 29:2384-9.
    pubmed
  • 5) Chou TC, Talalay P. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and fbr the quantitation of synergism and antagonism of chemotherapeutic tigents. In Harpar R, Connors A, eds. New Avenues in Developmental Cancer Chemotherapy, New York:Academic Press, 1987, pp, 37.
  • 6) Frei E III, Elias A, Wheeler C, et al. The relationship between high-dose treatment and combination chemotherapy. Clin Cancer Res. 1998; 4:2027-37.
  • 7) Skipper HE, Schabel FM Jr, Wrilcox WS. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep. 1964; 35:1-111.
  • 9) Norton L, Simon R. Tumor size, sensitivity to therapy, and the design of treatment schedule. Cancer Treat Rep. 1977; 61:1307-17.
    pubmed
  • 10) Norton L, Simon R. The Norton-Simon hypothesis revised. Cancer Treat Rep. 1986; 70:163:9.
  • 11) Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep. 1979; 63:1727-33.
  • 12) Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 1943; 28:491-511.
    pubmed
  • 14) Day RS. Treatment sequencing, asymmetry and uncertainly; protocol strategies for combination chemotherapy. Cancer Res. 1986; 46; 3876-85
  • 15) Norton L. Implications of kinetic heterogeneity in clinical oncology. Seminars in Oncology. 1985; 12:231-49.
    pubmed
  • 18) Sartorelli AC, Caresy WA. Combination chemotherapy. In:Holland JF, Fre E III, eds. Cancer Medicine 2nd ed. Philadelphia:Lea & Febiger, 1982, pp. 720.
  • 19) Schabel FM. The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumor. Cancer Res. 1969; 29:2384-9.
    pubmed
  • 21) DeVita VT. Principles of cancer management:Chemotherapy. In:DeVita VT, Hellman S, Rosenberg A, eds, Cancer. Principles & Practice of oncology. 5th edition, Philadelphia:Lippincott-Raven Publishers, 1997, pp. 257:83.
  • 25) Carter SK Livingston R. Principles of cancer chemotherapy. In:Carter SK et al. eds. Principles of Cancer Treatment MacGraw-Hill, 1982, pp. 92.
  • 26) 西條長宏, 小川一誠. がん化学療法. 臨床腫瘍学, 第2版, 有吉寛, 西條長宏, 佐々木康綱, 他編:日本臨床腫瘍研究会編, 1999, pp.423-62.
  • 29) Esaki T, Nakano S, Tatsumoto T, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum (II):induced DNA interstrand cross-link removal in HST-1 human squamous carcinoma cell line. Cancer Research. 1992; 52:6501-6.
    pubmed
  • 31) Plameri S, Trave F, Russello O, et al. The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platon. Sel Cancer Ther. 1989:5:169-77.
  • 33) 佐々木常雄. Levofolinate (1-leucovorin)-5-FU併用療法. 癌と化学療法. 2000; 27:31522.
  • 38) Donehower RC, Abeloff MD, Perry MC. Chemotherapy. In:Abeloff RC, et al. eds. Clinical Oncology, New York, Edin-burgh, London, Melboume, Tokyo:Churchhill Livingstone, 1995, pp. 201-18.
  • 46) 犬山征夫, 白土博樹. 頭頸部癌における化学療法併用放射線 療法. 癌の臨床. 1996; 42:2632.
  • 55) 白坂哲彦, 山光進, 木村弘通, 他. 癌化学療法への新しい治療法-5FUと少量連日CDDPとの併用療法の理論と実際 -. 血液腫瘍科. 1999; 39:40616.

P.158 掲載の参考文献

  • 2) Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Nature. 1997; 390:3356.
  • 5) Ueda K Clark DP, Chen CJ, et al. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem. 1987; 262:505-8.
    pubmed
  • 7) Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997:57:3537-47.
    pubmed
  • 9) Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996:56:4124-9.
    pubmed
  • 10) Mikami K Naito M, Tomida A et al. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res. 1996:56:2823-6.
    pubmed
  • 12) 田代田鶴子. 抗がん剤賦活化機構減弱による耐性獲得. 日本臨牀. 1997:55:1038-43.
  • 15) 古川学, 原田大志, 田中聡也, 桑野信彦. DNAトポイソメラーゼ阻害剤と耐性. 日本臨牀. 1997:55:1096-102.
    Medical*Online
  • 18) Scheper RJ, Broxterman 1-J, Scheffer GL, et al. Overexpres-sion of a M (r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993:53:1475-9.
  • 23) Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 1eukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by vera-pamil. Cancer Res. 1981; 41:1967-72.
  • 29) Nakano R, Oka M, Nakamura T, et al. A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leu-kotriene C4 ethux in lung cancer cells expressing multidrug resistance protein. Biochem Biophys Res Commun. 1998; 251:307-12.
  • 30) Jedlitschky G, Leier I, Buchholz U, et al. ATP-dependent transport of glutathione Sconjugates by the multidrug resistance-associated protein. Cancer Res. 1994:54:4833-6.
    pubmed
  • 35) 長沼章. メタロチオネイン. 日本臨牀. 1997:55:1091-5.
  • 42) Kitazono M, Ileda R, Sumizawa T, et al. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells (abstruct#1710). Proc Am Assoc Cancer Res. 2000; 41:268.
  • 44) Wilson WH, Sorbara L, Figg WD, et al. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine:presentation of a novel therapeutic paradigm. Clin Cancer Res. 2000; 6:415-21.
  • 45) 佐々木康綱. 耐性克服剤の臨床試験. 組織培養工学, 1999; 25:388-90.
  • 47) Bleyer WA New vistas for leucovorin in cancer chemotherapy. Carlcer. 1989; 63:9951007.
    pubmed

P.167 掲載の参考文献

  • 1) 河上裕. がん細胞排除機構. 感染と生体防御, 竹田美文, 渡邊武編. 岩波講座, 現代医学の基礎, 東京:岩波書店, 2000, p. 201-20.
  • 2) Principles and practice of the Biologic therapy of cancer, 3rd ed. Rosenberg SA. Ed. Philadelphia:Lippincott Williams & Wilkins, 2000.
  • 7) Naomoto Y, Tanaka N, Fuchimoto S, et al. In vitro synergistic effects of natural human tumor necrosis factor and natural human interferon-α. Jpn J Cancer Res. 1987; 78:87-92.
  • 8) Muro M, Naomoto Y, Orita K. Mechanism of the combined antitumor effect of natural human tumor necrosis factor-α and natural human interferon-α on cell cycle progression. Jpn J Cancer Res. 1991; 82:11-26.
  • 9) 田中紀章, 折田薫三, 猶本良夫. IFN-α, TNF-αによる5FU の Biochemical Modulation. 金丸龍之介, 小西敏郎 編. Biochemical Modulationの基礎と臨床, 東京:医学書院, 1995, pp.56-62.
  • 10) Wadler S, Schwartz ED. Antineoplastic activity of the combination of Interferon and cytotoxic agents against experimental and human malignancies. Cancer Res. 1990:51:3473-86.
  • 14) Kase S, Kubota T, Watanabe M, et al. Interferon beta increase antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Res. 1993; 13:369-74.
    pubmed
  • 21) Bemhard H, Klein O, Bushenfelde K et al. Treatment of refractory colorectal carcinoma With fluorouracil, folinic acid, and Interferon aifa-2a. Semi Oncol 1992; 19 (Suppl 3):204-7.
  • 29) 笹川 裕, 高後裕, 蟹沢祐司, 他. 癌性腹膜炎患者に対するII-2 activated killer細胞の局所移入療法. 医学のあゆみ. 1986; 138:841-2.
  • 30) 安元公正. 癌性胸膜炎に対するエフェクター機構とIL2臨床応用. 日本臨床免疫学会誌. 1988; 11:543-5.
  • 32) 藤本重義, 田中憲一. Adoptive immunotherapyの展開. 日癌治誌. 1988; 23:2047-9.
  • 41) Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of auto-logous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997:57:1537-46.
  • 45) Weh HJ, Plats D, Braumann D, et al. Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant Interferon alpha-2b:Preliminary data of a phase II study. Semi Oncol. 1992; 19:180-4.
  • 46) Hubeman M, McClay E, Atkins M, et al. Phase II trial of 5fluorouracil (5FU) and recombinant interferon-alpha-2a (IFN) in advanced colorectal cancer (abstract#478). Proc Am Soc Clin Oncol. 1991; 10:139.
  • 47) Douillard JY, Leborgne J, Danielou JY, et al. Phase II trial of sfluorouracil (5FU) and recombinant alpha interferon (Rα IFN) (Intron A) in metastatic, previously untreated colorectal cancer (CRC) (abstract#422). Proc Am Soc Clin Oncol. 1991; 10:139.
  • 48) 相羽恵介, 小川一誠, 水沼信之, 他. 進行大腸癌に対する5 fluorouracil (5-FU), Human Lymphoblastoid Interferon (HLBI) 併用療法の多施設共同研究 (抄録W5-10). 日癌治誌1992; 27:1279.

P.177 掲載の参考文献

  • 1) Kartner N, Shales M, Riorden JR, et al. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and cell-surface P-glycoprotein. Cancer Res. 1983; 43:4413-9.
  • 2) Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia, in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by vera-pamil. Cancer Res. 1981; 41:1967-72.
  • 4) 竹村譲. カルシウム拮抗剤を用いた多剤耐性(MDR)の克服. CLINICAL CALCIUM. 1995:5:10149.
  • 8) Yusa K Tsuruo T. Reversal mechanism of multidrug resis-kmce by verapamil:direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 1989; 49:5002-6.
  • 19) Leith CP, Chen IM, Kopecky KJ, et al. Correlation of multi-drug resistance (MDR1) protein expression with functional dye/dnlg efnux in acute myeloid leukemia by multiparame-ter flow cytometry:identication of discordant MDR-./Efflux' and MD+/Eflx-cases. Blood. 1995; 86:232942.
  • 21) Dietel M, Boss H, Reymann A, et al. In vivo reversibinty of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil. J Exp Ther Oncol. 1996; 1:23:9.
    pubmed
  • 24) Foxwell BM, Mackie A Ling V, et al. Idenfication of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol. 1989; 36:543-6.
  • 28) Arceci RJ, Stieglitz K Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the mul-tidrug resistance phenotype. Blood. 1992; 80:1528-36.
  • 29) Boesch D, Gaveriaux C, Jachez B, et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.Cancer Res. 1991; 51:4226-33.
    pubmed
  • 32) Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol.1996; 148:1237-47.
    pubmed
  • 33) Ramu A Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res. 1984; 44:4392-5.
    pubmed
  • 35) Samuels BL, Hollis DR, Rosner GL, et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen:acancer and leukemia group B study. Clin Cancer Res. 1997; 3:1977-84.
    pubmed
  • 36) Tsuruo T, Iida H, Tsukagoshi S, et al. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982; 42:4730-3.
    pubmed
  • 37) Inaba M, Nagashima K Non-antitumor vinca alkaloids reverse multidrug in P3881eukemia cells in vitro. Jpn J Cancer Res. 1986; 77:197-204.
    pubmed
  • 38) Starling JJ, Shepard RL, Cao J, et al. Pharmacological characterization of LY335979:apotent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 1997; 37:33547.
  • 41) Pierre A Dunn TA Kraus-Berthier, et al. In vitro and in vivo circumvention of multidrug resistance bt Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs. 1992; 10:137-48.
  • 50) Ito C, Ribeiro RC, Behm FG, et al. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood.1998; 91:1001-7.
    pubmed
  • 51) Cabot MC, Giuliano AE, Han TY, et al. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res. 1999; 59:880-5.
    pubmed
  • 52) Ganapathi R, Kuo T, Teeter L, et al. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Mol Pharmacol. 1991; 39:1-8.
    pubmed
  • 55) Chu E, Allegra CJ. Antifolates. In:Chabner BA, et al. eds. Cancer chemotherapy and biotherapy:Principles and Prac-tice, 2nd ed. Philadelphia:Lippincott-Raven Pub., 1996, pp. 109-48.
  • 59) Tew KD. Modulation of p-glycoprotein-mediated drug resistance. In:Tew KD, et al. eds. Preclinical and clinical modulation of anticancer drugs. Boca Raton Fla:CRC Press, 1993, pp. 12596.
  • 65) List AF, Kopecky KJ, Wihnan CL, et al. Benefit of cyclo-sprine (CsA) modulation of anthracycline resistance in high-risk AML:a Southwest Oncology Group (ASOG) study. Blood. 1998; 92 Suppl:312a
  • 67) Vanhoefer U, Cao S, Minderman H, et al. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resiskmce in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res. 1996; 2:36977.
  • 72) Jedlitschky G, Leier I, Buchholz U, et al. ATP-dependent transport of glutathione Sconjugates by the multidrug resistance-associated protein. Cancer Res. 1994; 54:4833-6.
    pubmed
  • 73) Jedlitschky G, Leier I, Buchholz U, et al. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conlugate export pump. Cancer Res. 1996; 56:988-94.
    pubmed
  • 74) Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994; 54:5902-10.
    pubmed
  • 77) anhoefer U, Cao S, Minderman H, et al. D, Lbuthionine-(S, R)-sulfoximine potentiates in vivo the therapeutic ethcacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996; 2:1961-8.

P.194 掲載の参考文献

  • 5) Yamamoto S, Yamamoto T, Kataoka T, et al. Unique pahndromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol. 1992; 148:4072-6.
    pubmed
  • 10) Corrias MV, Tonini G. An oligomer complementary to the 5:end region of MDRI gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res. 1992; 12:1431-8.
  • 11) Alahari SK, Dean NM, Fisher MH, et al. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5:cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1996; 50:808-19.
    pubmed
  • 17) Quattrone A Papucci L, Morganti M, et al. Inhibition of MDRI gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol Res. 1994; 6:311-20.
  • 21) Nakashima E, Matsushita R, Negishi H, et al. Reversal of drug sensitivity in MDR subline of P3881eukemia by gene-targeted antisense oligonucleotide. J pham Sci. 1995; M:12059.
  • 22) Cucco C, Calabretta B, In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 1996; 56:4332-7.
  • 28) Van Waardenburg RC, Prins J, Meijer C, et al. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res. 1996; 16:196370.
  • 41) Dorai T, Kobayashi H, Holland JF, et al. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammer-head ribozyme. Mol Pharmacol. 1994; 46:437-44.
  • 42) Kobayashi H, Dorai T, Holland JF, et al. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 1994; 54:1271-5.
    pubmed
  • 50) Potter PM, Harris LC, Remack JS, et al. Ribozyme-mediated modulation of human O6-methylguanine-DNA methyltrans-ferase expression. Cancer Res. 1993; 53:1731-4.
  • 58) Warashina M, Kuwabara T, Taira K. Comparison of activities between hammerhead hbozymes and DNA enzymes targeted to L6 BCR, ABL chimeric (b2a2) mRNA Nucleic Acids Symp Ser. 1997; 37:213-4.
    pubmed
  • 61) Tumer DH, Sugimoto N. RNA structure prediction. Annu Rev Biophys Chem. 1988; 17:167-92.
  • 63) 杉本直己. 最近接塩基対パラメータを用いた核酸の安定性予測とその機能との関係. 生物物理. 1993; 33:61-7.
  • 65) 川崎広明, 藁科雅岐, 多比良和誠. RNAヘリカーゼと相互作用する新規 RNA-protein ハイブリッド型リボザイムは標的mRNAの二次構造に関係なく切断できる. Antisense. 2000; 4:84.
  • 67) Sullenger BA Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors. Cytokines Mol Ther. 1996; 2:201-5.
    pubmed
  • 71) Seth P, Katayose D, Li Z, et al. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells:agene therapy approach for drug-resistant cancers. Cancer Gene Ther. 1997; 4:383-90.
  • 74) Allay JA Dumenco LL, Koc ON, et al. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood. 1995; 85:3342-51.
    pubmed
  • 75) Maze R, Carney JP, Kelley MR, et al. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1β-bis (2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc Natl Acad Sci USA. 1996; 93:206-10.

P.207 掲載の参考文献

  • 1) Takemura Y, Kobayashi H, Miyachi II. Cellular and molecular mechanisms of resistance to antifolate drugs:new analogues and approaches to overcome the resistance. Int J Hematol. 1997; 66:45977.
  • 5) Chu E, Allegra CJ. Antifolates. In:Chabner BA, Longo DL eds. Cancer Chemotherapy and Biotherapy:Principles and Prac-tice, 2nd ed. Philadelphia, PA Lippincott-Raven, 1996, pp. IW 48.
  • 9) Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Phamacol. 1980; 17:10510.
  • 12) Moscow JA Gong M, He R, et al. Isolation of a gene encoding ahuman reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 1995; 55:3790-4.
  • 13) Dixon KH, Lanpher BC, Chiu J, Kelley K, Cowan KH. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem. 1994; 269117-20.
  • 14) Williams FRM, Murray RC, Underhill TM, Flintoff WF. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J Biol Chem. 1994; 269:5810-6.
  • 17) Gong M, Yess J, Connolly T, Ohnuma T, et al. Molecular mechanism of antifolate transport-deficiency in a metho-trexate-resistant MOLTL3 human leukemia cell line. Blood. 1997; 89:24949.
  • 18) Gong M, Cowan KH, Moscow JA. RFCI allele mutations in human cell lines deficient in folate transport. Proc Am Assoc Cancer Res. 1996; 37:498.
  • 31) Guo W, Healey JH, Meyers PA et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 1999; 5:621-7.
    pubmed
  • 34) Ohnuma T, Lo RJ, Scanlon KJ, et al. Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro. Cancer Res. 1985; 45:1815-22.
    pubmed
  • 41) Jackman AL, Alison DL, Calvert AH, et al. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargy1-5, 8-dideazafolic acid (CB3717):development, characterization, and cross-resistance studies. Cancer Res. 1986; 46:2810-5.
  • 42) 0'Connor BM, Jackman AL, Crossley PH, et al. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-Mopropargyl-5, 8-dideazafolic acid:a novel folate-based thymidylate synthase inhibitor. Cancer Res. 1992; 52:1137-43.
  • 49) Srimatkandada S, Schweitzer BI, Moroson BA, et al. Amplification of a polymorphic dihydrofolate reductase gene ex-pressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J Biol Chem. 1989; 264:3524-8.
  • 51) Pizzomo G, Mini E, Coronnello M, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res. 1988; 48:2149-55.
  • 52) McCloskey DE, McGuire JJ, Russell CA et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF:CEM human leukemia sublines. J Biol Chem. 1991; 266:6181-7.
    pubmed
  • 65) Goker E, Lin JT, Trippett T, et al. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia. 1993; 7:1000-4.
    pubmed
  • 70) Goker E, Kheradpour A, Waltham M, et al. Acute monocytic leukemia:a myeloid leukemia subset that may be sensitive to methotrexate. Leukemia. 1995; 9:2746.
  • 74) 竹村 譲. 葉酸型チミジル酸合成酵素阻害剤の基礎と臨床. 癌の臨床. 1997; 43:647-58.
    Medical*Online
  • 75) Ohnoshi T, Ohnuma T, Takahashi I, et al. Establishment of methotrexate-resistant human acute lymphoblastic leukemic cells in culture and effects of folate antagonists. Cancer Res. 1982; 42:1655-60.
    pubmed
  • 76) Sirotnak FM, Moccio DM, Goutas LJ, et al. Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine. Cancer Res. 1982; 42:924-30.
  • 79) Haller DG. Trimetrexate:experience with solid tumors. Semin Oncol. 1997; 24(Suppl 18):71-6.
  • 81) Blanke CD, Messenger M, Taplin SC. Trimetrexate:review and current clinical experience in advanced colorectal cancer. Semin Oncol. 1997; 24(Suppl 18):57-63.
  • 82) Bertino JR. Biomodulation of 5-fluorouracil with antifolates. Semin Oncol. 1997; 24(Suppl18):52-6.
  • 86) Arkin H, Ohnuma T, Kamen BA, et al. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. Cancer Res. 1989; 49:6556-61.
  • 87) Assaraf YG, Molina A, Schimke RT. Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate. J Biol Chem. 1989; 264:1832-34.
  • 89) Habeck LL, Mendelsohn LG, Shih C, et al. Substrate specificity of mammalian folyl-polyglutamate synthetase for 5, 10 dideazatetrahydrofolate analogs. Mol Pharmacol. 1995; 48:326-33.
  • 93) Hughes AN, Rafi I, Griffin MJ, et al. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYM ITAQ) administered orally for 5 days. Clin Cancer Res. 1999; 5:111-8.
  • 94) Mauritz R, Bekkenk MW, Rots MG, et al. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res. 1998; 4:2399-410.
    pubmed
  • 95) Rots MG, Pieters R, Peters GJ, et al. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood.1999; 94:3121-8.
    pubmed
  • 96) Antony AC. The biological chemistry of folate receptors. Blood. 1992; 79:2807-20.
    pubmed
  • 98) Schilsky RL. Antimetabolites 1. Methotrexate. In:Perry MC ed. The Chemotherapy Source Book. Balltimore, MD:Williams & Wilkins, 1992, pp.301-6.
  • 100) Kamps WA, Bokkerink JP, Hahlen K, et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy:results of Dutch Childhood Leukemia Study Group Protocol ALL7 (1988-1991). Blood. 1999; 94:1226-36.
  • 102) Reiter A Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy:a report of the Berlin-Frankfurt-Munster Group Trial NHLBFM 90. Blood. 1999; 94:3294-306.
    pubmed
  • 106) Kobayashi H, Halatsch ME, Takemura Y, et al. Cleavage of human dihydrofolate reductase RNA by a hairpin ribozyrne. J Natl Def Med Coll. 1996; 21:99-102.
  • 111) Mareya SM, Sorrentino BP, Blakley RL. Protection of CCRF-CEM human lymphoid cells from antifolates by retroviral gene transfer of variants of murine dihydrofolate reductase. Cancer Gene Ther. 1998; 5:225-35.
    pubmed
  • 112) Mineishi S, Nakahara S, Takebe N, et al. Purine salvage rescue by xanthineguanine phosphoribosyltransferase (XGPRT) potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Cancer Gene Ther. 1998; 5:144-9.
    pubmed

P.220 掲載の参考文献

  • 1) Grem JL. 5-Fluoropyrimidines. In:Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy:Principles and Practice, 2nd ed. Philadelphia:Lippincott-Raven, 1996, pp.149-211.
  • 2) Gorlick R, Bertino JR. Drug resistance in colon cancer. Semin Oncol. 1999; 26:606-11.
    pubmed
  • 3) Chu E, Allegra CJ. Antifolates. In:Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, Philadelphia:Lippirlcott-Raven, 1996, pp.149-211.
  • 4) Berger SH, Jenh C-H, Johnson LF, et al. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol. 1985; 28:461-7.
    pubmed
  • 5) Shibata J, Aiba K Shibata H, et al. Detection and quantitation of thymidylate synthase mRNA in human colon adeno-carcinoma cell line resistant to 5-fluorouracil by competitve PCR. Anticancer Res. 1998; 18:1457-64.
  • 6) Barbour KWr, Berger SH, Berger FG. Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol Pharmacol. 1990; 37:5158.
  • 10) Wang F-S, Aschele C, Sobrero A, et al. Decreased folylpolyglutamate synthetase expression:a novel mechanism of fluorouracil resistance. Cancer Res. 1993; 53:3677-80.
    pubmed
  • 14) Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of y interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res. 1990; 50:5834-40.
  • 17) Keyomarsi K Samet J, Molnar G, Pardec AB. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem. 1993; 268:15142-9.
  • 18) Allegra C, Chu E. Strategies designed to inhibit the catalytic activity of thymidylate synthase (extended abstr). Proc Am Ass Cancer Res. 1996; 37:651.
  • 20) Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 1981; 41:3288-95.
    pubmed
  • 21) Yin DM, Zakrzewski SF, Hakala MT. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharm. 1982; 23:190-7.
  • 23) Keyomarsi K Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res. 1986; 46:5229-35.
    pubmed
  • 25) 相羽恵介, 大澤浩, 小川一誠. LV/5FU. 金丸龍之介, 小西敏郎 編 Biochemical Modulationの基礎と臨床, 東京:医学書院, 1995, pp.2939.
  • 28) 下山正徳, 木村禧代二. 各種抗がん剤のin vitroにおける殺細胞効果について:L-1210細胞を中心に. 最新医学. 1973; 28:1024-40.
  • 30) Takimoto CH, Yee LK, Venzon DJ, et al. High inter-and intrapatient variation in 5-fluorouracil plasma concentrations dudng a prolonged drug infusion. Clin Cancer Res.1999; 5:1347-52.
    pubmed
  • 32) Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protoracted continuous infusiofi. Cancer Res. 1990; 50:197-201.
    pubmed
  • 33) Hrushesky WJM. Circadian pharmacodynamics of anticancer therapies. Clin Chem. 1993; 39:2416-8.
  • 34) Zhang R, Lu Z, Liu T, et al. Relationship between circadian-dependent toxicity of sfluorodeoxyuridine and circadian rhythms of pyrimidine enzymes:possible relevance to fluoro-pyrimidine chemotherapy. Cancer Res. 1993; 53:2816-22.
  • 36) Porter DJT, Chestnut WG, Merrill BM, et al. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem. 1992; 267:5236-42.
  • 37) Mani S, Beck T, Chevlen E, et al. A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC) (abstract#1083). Proc Am Soc Clin Oncol. 1998; 17:281a.
  • 38) Tatsumi K Fukushima M, Shirasaka T, et al. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extract. Jpn J Cancer Res. 1987; 78:748-55.
    pubmed
  • 39) Shirasaka T, Shimamoto Y, Fukushima M. Inhibition of oxonic acid on gastric intestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993; 53:4004-9.
  • 41) Taguchi T, Inuyama Y, Kanamaru R, et al. Phase I study of S-1.Jpn J Cancer Chemother. 1997; 24:2253-64.
  • 43) Inuyama Y, Kida A, Tsukuda M, et al. Early phase II study of S-1 in patients with advanced head and neck cancer. Jpn J Cancer Chemother. 1998; 25:1151-8.
  • 44) Taguchi T, Morimoto K, Horikoshi N, et al. An early phase II clinical study of S-1 in patients with breast cancer. Jpn J Can-cer Chemother. 1998; 25:1035-43.
  • 45) Hino M, Kudoh S, Furuse K, et al. Early phase II study of S-1 in patients with non-small-cell lung cancer (abstract #503). Ann Oncol. 1996; 7(Suppl 5):105.
  • 47) Kurihara M, Koizumi W, Hasegawa K, et al. Late phase II study of S-1, a novel oral fluoropyrimi (line derivative, in patients with advanced gastric cancer (abstract #1007). Proc Am Soc Clin Oncol. 1998; 17:262a.
  • 48) Baba H, Ohtsu A Sakata Y, et al. Late phase II study of S-1 in patients with advanced colorectal cancer in Japan (abstract #1065). Proc Am Soc Clin Oncol. 1998; 17:277a.
  • 49) Endo S, Niwa H, Kida A, et al. Late phase II study of S-1 in patients with head and neck cancer (abstract #1526). Proc Arn Soc Clin Oncol. 1999; 18:3959.
  • 50) Sano M, Saeki T, Takashima S, et al. Late phase II study of S-1 in patients with advanced and/or recurrent breast cancer (abstract #404). Proc Am Clin Oncol. 2000; 19:105.
    pubmed
  • 51) 吉森浩三, 河原正明, 畝川芳彦, 他. 非小細胞肺癌患者を対 象としたS-1後期臨床第二相試験 (abstract #2). 日癌治誌. 1999; 34:213.
  • 52) 田口鐵男. 5:-DFUR (Doxifluridine). 癌と化学療法. 1987; 14:2235-43.
  • 53) Ishikawa T, Utoh M, Sawada N, et al. Xeloda (Capecitabine) an orally available tumor selective fluoropyrimidine carbamate (abstract #727). Proc Am Soc Clin Oncol. 1997; 16:208a.
  • 56) 佐伯俊昭, 高嶋成光, 寺島雅典, 他. 進行・再発乳癌患者を対象とした Ro09-1978 (Capecitabine) の前期臨床第H相試験(abstract #2). 日癌治誌. 1999; 34:222.
  • 57) 寺島雅典, 小泉和三郎, 氏家重紀, 他. 進行・再発胃癌患者を対象とした Ro09-1978 (Capecitabine) の前期臨床第H相試験 (abstract #4). 日癌治誌1999; 34:222.
  • 58) 近藤征文, 佐藤 温, 寺島雅典, 他. 進行・再発結腸・直腸癌患者を対象とした Ro09-1978 (Capecitabine) の前期臨床第II相試験 (abstract #3). 日癌治誌1999; 34:222.
  • 59) Hande KR, Garrow GC. Purine Antimetabolites, In:Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Principles and practice, 2nd ed, Philadelphia:Lippincott-Raven, 1996, pp.235-52.
  • 60) 宮脇修一, 今村雅寛, 小林祥子, 他. 慢性リンパ性白血病に対する SH L 573 (Fludarabine Phosphate) の第II相臨床試験. 臨床血液. 1999; 40:1236-44.
  • 61) Mansson E, Spasokoukotskaja T, Sallstrom J, et al. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res. 1999; 59:5956-63.

P.230 掲載の参考文献

  • 1) Evans JS, Musser EA, Mengel GD, et al. Antitumor activity of 1-β-D-arabinofuranosylcytosine hydrochloride. Proc Soc Exp Biol Med. 1961; 106:350-3.
  • 2) Ueda T, Nakamura T, Ando S, et al. Pharmacokinetics of N4-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res. 1983; 43:3412-6.
  • 3) Ueda T, Kamiya K, Urasaki Y, et al. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. Cancer Res. 1994; 54:109-13.
  • 4) 松田彰. 抗がん活性を有する新規核酸系代謝拮抗剤の開 発と今後の課題- overview に代えて-. プリン・ピリミジン代謝. 1988; 22:177-80.
  • 6) Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2', 2'-d Muoro-2'-deoxycytidine). Cancer Res. 1990; 50:4417-22.
    pubmed
  • 7) Jamieson GP, Finch LR, Snook M, et al. Degradation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate in human leukemia myeloblasts and lymphoblasts. Cancer Res. 1987; 47:3130-5.
  • 10) 神谷健一, 内田三千彦, 上田孝典, 他. Ara-C三燐酸の人白血病細胞内動態からみたara-C投与法の基礎的検討. 日癌治誌. 1990; 25:1419-27.
  • 11) Inagaki A, Nakamura T, Wakisaka G. Studies on the mechanism of action of 1-β-D-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes. Cancer Res. 1969; 29:2169-76.
  • 12) Kufe DW, Major PP, Egan EM, et al. Correlation of cytotoxicity with incorporation of ara-C into DNA J Biol Chem. 1980; 255:8997-9000.
  • 13) Townsend AJ, Cheng YC. Sequence-specific effects of ara-5 aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in vitro:visualization of chain elongation on a defined template. Mol Pharmacol. 1987; 32:3309.
  • 14) Ohno Y, Spriggs D, Matsukage A, et al. Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase β. Cancer Res. 1988; 48:1494-8.
  • 16) Takauji R, Yoshida A, lwasaki H, et al. Enhancement of Ca2+-dependent endonuclease activity in L1210 cells during apoptosis induced by 1-β-D-arabinofuranosylcytosine:possible involvement of activating factor(s). Jpn J Cancer Res. 1995; 86:677-84.
  • 17) Ho DHW, Frei E III. Clinical phamlacology of 1-β-D-arabinofuranosylcytosine. Clin Pharmacol Ther. 1971; 12:944-54.
  • 18) Kishi S, Goto N, Nakamura T, et al. Evaluation of cell-killing effects of 1-β-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Cancer Res. 1999; 59:2629-34.
  • 20) Owens JK Shewach DS, Ullman B, et al. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. 1992; 52:2389-98.
  • 21) Richel DJ, Colly LP, Arkesteijn GJA, et al. Substrate-specific deoxycytidine kinase deficiency in 1-β-D-arabinofuranosyl-cytosine-resistant leukemic cells. Cancer Res. 1990; 50:6515-9.
  • 23) Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. 1985; 12:20-30.
    pubmed
  • 25) Abe I, Saito S, Hori K et al. Role of dephosphorylation in accumulation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res. 1982; 42:2846-51.
  • 26) de Saint Vincent BR, Butthl G. Studies on 1-β-D-arabinofuranosylcytosine-resistant mutants of Chinese hamster fibroblasts:W. Altered regulation of CTP synthetase generates arabinosylcytosine and thymidine resistance. Biochim Biophys Acta. 1980; 610:352-9.
  • 27) de Saint Vincent BR, Dechamps M, Buttin G. The modulation of the thymidine triphosphate pool of Chinese hamster cells by dCMP deaminase and UDP reductase. J Biol Chem. 1980; 255:162-7.
    pubmed
  • 28) Mancini WR, Cheng YC. Human deoxycytidylate deaminase. Substrate and regulator specificities and their chemotherapeutic implications. Mol Phamacol. 1983; 23:159-64.
  • 29) Leclerc JM, Cheng YC. Demonstration of activities in leukemic cells capable of removing 1-β-D-arabinofuranosylcytosine (ara-C) from ara-C incorporated DNA (abstract). Proc Am Assoc Cancer Res. 1984; 25:19.
  • 30) Dicioccio RA, Srivastava BIS. Kinetics of inhibition of deoxynucleotidepolymerizing enzyme activities from normal and leukemic human cells by 9-fi-D-arabinofuranosyladenine 5'-triphosphate and 1-β-D-arabinofuranosylcytosine 5'-triphosphate. Eur J Biochem. 1977; 79:411-8.
  • 31) Pourquier P, Takebayashi Y, Urasaki Y, et al. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci USA 2000; 97:1885-90.
  • 33) Wang S, Vrana JA Bartimole TM, et al. Agents that downregulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol. 1997; 52:1000-9.
  • 34) Rauscher F III, Cadman E. Biochemical and cytoldnetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-β-D-arabinofuranosylcytosine metabolism and cytotoxicity. Cancer Res. 1983; 43:2688-93.
  • 35) Roberts D, Peck C, Hillard S, et al. Methotrexate-induced changes in the levels of 1-β-D-arabinofuranosylcytosine triphosphate in L1210 cells. Cancer Res. 1979; 39:4048-54.
  • 37) Kem DH, Morgan CR, Hildebrand-Zanki SU. In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine:synergy of antitumor activity with cis-diamminedichloroplatinum (II). Cancer Res. 1988; 48:117-21.
  • 38) Ho DHW, Carter CJ, Brown NS, et al. Effects of tetrahydrouridine on the uptake and metabolism of 1-β-D-ararabinofuranosylcytosine in human normal and leukemic cells. Cancer Res, 1980; 40:2441-6.
  • 39) Wong PP, Currie VE, Mackey RW, et al. Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat Rep. 1979; 63:1245-9.
    pubmed
  • 43) Donehower RC, Karp JE, Burke PJ. Phamlacology and toxicity of highdose Cytarabine by 72-hour continuous infusion. Cancer Treat Rep. 1986; 70:1059-65.
    pubmed
  • 44) Parker WB, Cheng YC. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol Pharmacol. 1987; 31:146-51.
    pubmed
  • 46) Bishop JF, Matthews Jp, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87:1710-7.
    pubmed
  • 47) Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia:the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cyytarabine with daunorubicin and 6-thioguanine:a randomized trial by the German AML Cooperative Group. Blood. 1999; 93 4116-24.
    pubmed
  • 50) 上田孝典, 中村徹. 急性白血病の化学療法. 日本医事新報. 1995; 3701:9-16.
    Medical*Online
  • 52) Avramis VI, Wiersma S, Krailo MD, et al. Pharmacokinetic and phamacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res. 1998; 4:45-52.
  • 53) Gandhi V, Kemena A, Keating MJ, et al. Fludarabine infusion potentiates arabinosylcytosine metabohsm in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992; 52:897-903.
    pubmed
  • 57) Huang P, Chubb S, Hertel LW, et al. Action of 2', 2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991; 51:6110-7.
    pubmed
  • 58) Goan YG, Zhou B, Hu E, et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycytidine in the human KB cancer cell hne. Cancer Res. 1999; 59:4204-7.
  • 60) Glover AB, Leyland-Jones B. Biochemistry of azacytidine:a review. Cancer Treat Rep. 1987; 71:959-64.
    pubmed

P.240 掲載の参考文献

  • 4) Goldenberg GJ, Vanstone CL Israels JG, et al. Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and-resistant L5178Y lymphoblasts. Cancer Res. 1970; 30:2285-91.
  • 5) Redwood WR, Colvin M. Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res. 1980; 40:1144-9.
    pubmed
  • 8) Pegg AE. Alkylation and subsequent repair of DNA after exposure to dimethylnitrosamine and related carcinogens. Rev Biochem Toxicol. 1983; 5:83-133.
  • 18) Hall AG, Matheson E, Hickson ID, et al. Purrication of an α class glutathione transferase from melphalan-resistant Chinese hamster ovary cells and demonstration of its ability to catalyze melphalan-glutathione adduct formation. Cancer Res. 1994; 54:3369-72.
  • 19) Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione Stransferase isozymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 1994; 54:6215-20.
    pubmed
  • 20) Schecter RL Woo A Duong M, et al. In vitro and in vivo mechanisms of drug resistance in a rat mammary carcinoma model. Cancer Res. 1991; 51:1434-42.
  • 21) Niitsu Y, Takahashi Y, Saito T, et al. Serum GST-π as a tumor marker for gastrointestinal malignancies. Cancer. 1988; 63:317-23.
  • 22) Hirata S, Odajima T, Kohama G, et al. Significance of Glutathione S-Transferase-π as a tumor marker in patients with oral cancer. Cancer. 1992; 70:2381-7.
  • 23) Kagi JHR. Evolution, structure and chemical activity of class Imetallothioneins:an overview. In:Suzuki KT, Imura N, Kimura M, eds. Metallothionein III, Basel, Switzerland:Birkhauser Verlag, 1993, pp.2955.
  • 26) Teicher BA, Holden SA, Kelly MJ, et al. Characterization of ahuman squamous carcinoma cell line resistant to cis-diamminedichloroplatinum (II). Cancer Res. 1987; 47:389-93.
  • 28) Tobey RA, Enger MD, Griffith JK, et al. Zinc-induced resistance to alkylating agent toxicity. Cancer Res. 1982; 42:2980-4.
    pubmed
  • 29) Berhane K, Hao XY, Egyhazi S, et al. Contribution of glutathione transferase M3-3 to 1,3-bis (2-chloroethyl)-1-nitrosourea resistance in a human non-small cell lung cancer cell line. Cancer Res. 1993; 53:4257-61.
  • 31) Sladek NE, Landkamer GL. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorines-resistant L1210 and crosslinking agent-resistant P388 cell lines. Cancer Res. 1985; 45:1549-55.
  • 32) Hilton J. Role of aldehyde dehydrogenase in cyclophos-phamide-resistant L1210 leukemia. Cancer Res. 1984; 44:5156-60.
  • 38) Kokkinalds DM, Moschel RC, Pegg AE, et al. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1, 3-bis(2-chloroethyl) 1-nitrosourea. Clin Cancer Res. 1999; 5:3676-81.
  • 39) Panella Tl, Smith DC, Schold SC, et al. Modulation of O6-alkylguanine-DNA alkyltranferase-mediated carmustine resistance using streptozotocin:a phase I trial. Cancer Res. 1992; 52:2456-9.
  • 40) Marathi UK Dolan ME, Erickson LC. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, strepto-zotocin, and 1, 3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Biochem Pharmacol. 1994; 48:2127-34.
  • 43) Britten CD, Rowinsky EK, Baker SD, et al. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res. 1999; 5:1629-37.
    pubmed
  • 44) Harris LC, Marathi UK Edwards CC, et al. Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin Cancer Res. 1995; 1:1359-68.
    pubmed
  • 45) Marathi UK Harris LC, Venable CC, et al. Retroviral transfer of a bacterial alkyltransferase gene (ada) into human bone marrow cells protects against O6-benzylguanine plus 1, 3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Clin Cancer Res. 1997; 3:301-7.
    pubmed
  • 47) Maze R, Kurpad C, Pegg AE, et al. Retroviral-mediated expression of the P140A, but not P140A/G156A mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethyhlitrosourea treatment. J Pharmacol Exp Ther. 1999; 290:1467-74.
  • 48) Magni M, Shammah S, Schiro R, et al. Induction of cyclo-phosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood. 1996; 87:1097-103.
  • 49) Moreb JS, Maccow C, Schweder M, et al. Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J Pharmacol Exp Ther. 2000; 293:390-6.
    pubmed
  • 54) Lacreta FP, Brennan JM, Nash SL et al. Pharmacokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther. 1994; 270:1186-91.
  • 55) Tew KD, Bomber AM, Hoffman SI, et al. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res. 1988; 48:3622-5.
  • 56) O'Dwyer PJ, LaCreta F, Nash S, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 1991; 51:6059-65.
    pubmed
  • 58) Hall A, Robson CN, Hickson ID, et al. Possible role of inhibition of glutathione S-transferase in the partial reversal of chlorambucil resistance by indomethacin in a Chinese hamster ovary cell line. Cancer Res. 1989; 49:6265-8.
  • 59) Satoh M, Kloth DM, Kadhim S, et al. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis. Cancer Res. 1993; 53:1829-32.
    pubmed
  • 60) Nagamura A Satoh M, Imura N. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum (II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res. 1987; 47:983-7.
  • 61) Kondo Y, Satoh M, Imura N, Akimoto M. Tissue-specific induction of metallothionein by bismuth as a promising protocol for chemotherapy with repeated administration of cis-diamminedichloroplatinum (II) against bladder tumor. Anticancer Res. 1992; 12:2303-7.
    pubmed

P.256 掲載の参考文献

  • 5) Ozols RF. Current status of chemotherapy for ovarian cancer. Semin Oncol. 1995; 22:61-6.
    pubmed
  • 10) 平林光司. Neoadjuvant chemotherapy. 癌の臨床 1997; 43:1371-80.
    Medical*Online
  • 12) Schilder RJ, LaCreta FP, Perez RP, et al. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res. 1994; 54:709-17.
  • 18) Mamenta EL, Poma EE, Kaufman WK, et al. Enhanced replicative bypass of platinum DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994; 54:3500-5.
  • 19) Harrap KR. Initiatives with platinum-and quinozoline-based antitumor molecules. Fourteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995; 55:2761-8.
  • 20) Kelland LR, Murrer BA, Abel G, et al. Ammine/amine platinum IV dicarboxrylates:a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1992; 52:822-8.
    pubmed
  • 25) Taniguchi K, wada M, Kohno K et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human ovarian cancer cell lines with decreased drug accumulation. Cancer Res. 1996; 56:4124-9.
  • 26) Ishihama T, Ali-Osman F. Glutathione-associated cis-diammine-dichloroplatinum (II) metabolis and ATP-dependent efflux from leukemia cells. J Biol Chem. 1993; 268:20116-25.
  • 30) Meijer C, Mulder NH, Timmer-Bosscha H, et al. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992; 52:6885-9.
  • 35) Yao KS, Godwin AK, Johnson Sw, et al. Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res. 1995; 55:4367-74.
  • 36) Kikuchi Y, Hirata J, Yamamoto K, et al. Altered expression of γ-glutamylcysteine synthetase, metallothionein and topo-isomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells. Jpn J Cancer Res. 1997; 88:213-7.
  • 37) Pottanaik A, Bachowski G, Laib J, et al. Properties of the reaction of cis-diamminedichloroplatinum (II) with metal-lothionein. J Biol Chem. 1992; 267:16121-5.
  • 39) Kondo Y, woo ES, Michalska AE, et al. Metallothionein null cells have increased sensitivity to anticancer drugs. Cancer Res. 1995; 55:2021-3.
    pubmed
  • 40) Yokomizo A, Ono M, Nanri H, et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicine, and etoposide. Cancer Res. 1995; 55:4293-6.
    pubmed
  • 43) Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced expression in ovarian carcinoma cell systems. Cancer Res. 1996; 56:556-62.
    pubmed
  • 44) Kikuchi Y, Hirata J, Ishii K, et al. Complexity of cis-diammine-dichloroplatinum (II) resistance mechanism in human ovarian cancer cells. In:Kikuchi Y, ed, The Mechanism of Cisplatin Resistance and its Circumvention. Nova Science Publishers, Inc, New York, 1998, pp.157-74.
  • 50) Chu G. Cellular response to cisplatin. J Biol Chem. 1994; 269:787-90.
    pubmed
  • 56) Bramson J, Panasci LC. Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damazing agents. Cancer Res. 1993; 53:3237-40.
    pubmed
  • 62) Hughes EN, Engelsberg BN, Billings PC. Purification of nuclear proteins that bind to cisplatin-damaged DNA:identity with high mobility group protein 1 and 2. J Biol Chem. 1992; 267:13520-5.
    pubmed
  • 65) Masuda H, Ozols RF, Lai G-M, et al. Increased DNA repair as a mechanism of acquired resistance to cis-dimminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 1988; 48:5713-6.
  • 67) Kern DH, Morgan CR, Hildebrand-Zauki SU. In vitro pharmacodynamics of 1-β-D-arabinofuranocylcytosine synergy of antitumor activity with cis-diamminedichloroplatinum (II). Cancer Res. 1988; 48:117-21.
  • 68) Peters GJ, Bergman AM, van Harperen VWTR, et al. Interactions between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22 (suppl 11):72-8.
  • 69) Yang L-Y, Li L, Keating MJ, et al. Arabynosyl-2-fluoadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharm. 1995; 47:1072-8.
  • 70) Johnson Sw, Swiggard PA, Handel LM, et al. Relationship between platinum-DNA adducts formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and-resistant human ovarian cancer cells. Cancer Res. 1994; 54:5911-6.
    pubmed
  • 71) Hamaguchi K Godwin AK Yakushiji M, et al. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993; 53:5225-32.
    pubmed
  • 73) Mamenta EL, Poma EE, Kaufman WK, et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994; 54:3500-5.
  • 74) Hoffman J-S, Pillaire M-J, Maga G, et al. DNA polylmerase β bypasses in vitro a single d(GpG)-cisplatin adducts placed on codon 13 of the HRAS gene. Proc Natl Acad Sci USA. 1995; 92:5356-60.
  • 76) Isonishi S, Hom DK, Thiebaut FB, et al. Expression of the c-Ha-Ras oncogene induces resistance to cisplatin. Cancer Res. 1991; 51:5903-7.
  • 77) Chapman RS, whetton AD, Chrestra CM, et al. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. Mol Pharm. 1995; 48:334-8.
  • 79) McClay EF, Albright KD, Jones JA, et al. Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res, 1992; 52:6790-6.
  • 81) Chang M-J, Yu w-D, Reyno LM, et al. Potentiation by interleukin 1α of cisplatin and carboplatin antitumor activity:schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res. 1994; 54:5380-6.
  • 82) Isonishi S, Jekunim AP, Hom DK, et al. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bembesin and tumor necrosis factor-α. J Clin Invest. 1992; 90:143-40.
  • 83) Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the C-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991; 51:4575-9.
  • 87) Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996; 56:556-62.
    pubmed
  • 88) Fan S, El-Deiry WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 1994; 54:5824-30.
    pubmed
  • 89) Fan S, Smith ML, River DJ II, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 1995; 55:1649-54.
  • 90) Eliopoulos AG, Kerr DJ, Ferod J, et al. The control of apoptosis and drug resistance in ovarian cancer:influence of p53 and Bcl-2.Oncogene. 1995; 11:1217-21.
  • 91) Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensltivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994; 54:2287-91.
    pubmed
  • 94) Armstrong DK, Kaufman SH, Ottaviano YL, et al. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res. 1994; M:5280-3.
  • 97) Moolenaar WH, Tertoolen GJ, de Laat Sw. Growth factors immediately raise cytoplasmic free Ca?+in human fibroblasts. J Biol Chem. 1984; 259:8066-9.
  • 98) Diamond I, Legg A, Schneider JA, et al. Glycolysis in quiscent cultures of 3T3 cens. J Biol Chem. 1978; 253:866-71.
  • 101) Pandiella A, Magni M, Lovisolo D, et al. The effects of epidermal growth factor on membrane potential. J Biol Chem. 1989; 264:1291-21.
  • 102) Pike LJ, Eakes AT. Epidermal growth factor stimulates the production of phosphatidylinositol monophosphate and the break down of polyphosphoinositides in A431 cells. J Biol Chem. 1987; 262:164-51.
  • 104) Novak-Hofer I, Thomas G. Epidemal growth factor-mediated activation of an S6 kdnase in Swiss mouse 3T3 cells. J Biol Chem. 1985; 260:10314-9.
  • 110) Liu B, Crijic ME, letzt A, Chin K-V. Cisplatin resistance and regulation of DNA repair in cAMP-dependent protein kinase mutants. Cell Growth Dfierentiation. 1996; 7:1105-12.
  • 111) Ohmori T, Arteaga CL. Protein kinase Cε transduction and phosphorylation by cis-diarnminedichloroplatinum (II) (CDDP):Potential role in CDDP-mediated cytotoxicity. Cell Growth Differentiation. 1998; 9:345-53.
  • 116) 石井賢治, 杉田道夫, 片岡良孝, 他. 子宮頸部上皮内病変におけるDNA ploidyに関する研究. 日産婦誌. 1997; 49:2154-62.
  • 124) Gralla JD, Sasse-Dwight S, Poljak LG. Formation of blocking lesions at identical DNA sequences by the nitrosourea and platinum classes of anticancer drugs. Cancer Res. 1987; 47:5092-6.
    pubmed
  • 126) Balcarova Z, Mrazek J, Kleinwachter V, et al. Cleavage by restriction enzymes of DNA modified with the antitumour drug cis-diamminedichloroplatinum (II). Gen Physiol Biophys. 1992; 11:579-88.
    pubmed
  • 133) Kudoh K, Takano M, Koshikawa T, et al. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res. 1999; 5:2526-31.
    pubmed
  • 134) Dodson MK, Hartmann LC, Chby WA, et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res. 1993; 53:445-60.
  • 138) Offit K, Wong G, Filippa DA, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma:clinical correlations. Blood. 1991; 77:1508-15.
    pubmed
  • 140) Gibson AA, Harwood FG, Tillman DM, et al. Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 Over-expression. Clin Cancer Res. 1998; 4:145-52.
  • 156) Gosland M, Lum B, Schimmelpfennig J, et al. Revies of therapeutics:Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy. 1996; 16:16-39.
  • 157) 菊池義公. シスプラチン耐性卵巣癌の耐性機構とその克服および効果増強. 血液・腫瘍科. 1996; 32:199-209.
  • 158) Marverti G, Andrews PA. Stimulation of cis-diamminedichloroplatinum (II) accumulation by modulation of passive permeability with genistein:an altered response in accumulation-defective resistant cells. Clin Cancer Res. 1996; 2:991-9.
    pubmed

P.267 掲載の参考文献

  • 1) 滝田智久. ブレオマイシンの化学. 蛋白核酸酵素 (別冊) 1-7 (ペプレオ文献集基礎より). 日本化薬株式会社.
  • 2) 藤井一省. 頭頸部悪性腫瘍に対する制癌剤治療についての臨床的研究- Bleomycinを中心として-. 耳鼻臨床. 1974; 67:367-89.
  • 3) 犬山征夫, 村上泰, 甲能直幸, 他. 頭頸部悪性腫瘍に対するNK-631 (Peplomycin) の臨床効果. 耳鼻臨床. 1978; 71:1517-27.
  • 4) 鈴木日出夫. (特集) 抗癌剤の最近の話題, 抗癌剤の耐性とその対策医薬ジャーナル. 1991; 27:51928.
  • 5) 田中基裕, 佐々木琢磨. (特集) 抗癌剤の耐性とその克服, 抗癌剤の耐性機序5) ブレオマイシン. 医薬ジャーナル. 1998; 34:195-3.
  • 6) Miyaki M, Ono T, Hori S, et al. Binding of bleomycin to DNA in bleomycin-sensitive and resistant rat ascites hepatoma cells. Cancer Res. 1975; 35:2015-9.
    pubmed
  • 10) Lazo JS, Braun ID, Labaree DC, et al. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by libromycin. Cancer Res. 1989; 49:185-90.
    pubmed
  • 14) 田中一仁. 頭頸部癌細胞株を用いた抗癌剤の交叉耐性に関する研究-cisplatin, 5fluorouracil, methotrexate, bleomycin 各耐性株における検討-. 慶応医学. 1997; 7:213-30.
  • 15) 犬山征夫. 第13章 薬剤耐性克服およびSecond Line Chemotherapyの開発に関する基礎的臨床的研究 (pp. 35370), 第11章 姑息的治療としての化学療法 (pp.31527). 犬山征夫, 編 著, 頭頸部癌治療における化学療法の役割, 東京:東京医学社, 1997.
  • 17) Jani Jp, Mistry JS, Morris G, et al. In vivo circumvention of human colon carcinoma resistance to bleomycin. Cancer Res. 1992; 52:2931-7.
    pubmed

P.275 掲載の参考文献

  • 2) Bachur NR, Yu F, Johnson R, et al. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol. 1992; 41:993-8.
    pubmed
  • 4) Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997; 54:1-7.
    pubmed
  • 6) Wingard LB, Jr, Tritton TR, Egler KA. Cell surface effects of adriamycin and caminomycin immobilized on cross-linked polyvinyl alcohol. Cancer Res.1985; 45:3529-36.
    pubmed
  • 10) Shapiro AB, Ling V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol Scand Suppl. 1998; 643:227-34.
    pubmed
  • 14) Almquist KC, Loe DW, Hipfher DR, et al. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell. Cancer Res. 1995; 55:102-10.
  • 17) Slovak ML, Ho JP, Bhardwaj G, et al. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 1993; 53:3221-5.
    pubmed
  • 18) Krishnamachary N, Ma L, Zheng L, et al. Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol Res. 1994; 6:119-27.
    pubmed
  • 19) Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994; 54:5902-10.
    pubmed
  • 20) Nooter K, Westerman AM, Flens MJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res. 1995; 1:1301-10.
    pubmed
  • 21) Scheffer RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M (r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993; 53:1475-9.
  • 26) Filipits M, Drach J, Pohl G, et al. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res. 1999; 5:2426-30.
    pubmed
  • 27) Arts HJ, Katsaros D, de Vries EG, et al. Drug resistance associated markers P-glycoprotein, multidrug resistance associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res. 1999; 5:2798-805.
  • 28) Damiani D, Michieli M, Ermacora A, et al. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. Haematologica. 1998; 83:290-7.
  • 32) Ciocca DR, Fuqua SA, Lock-Lim S, et al. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 1992; 52:3648-54.
    pubmed
  • 33) Huot J, Roy G, Lambert H, et al. Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. Cancer Res. 1991; 51:5245-52.
    pubmed
  • 34) Oesterreich S, Weng CN, Qiu M, et al. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993; 53:4443-8.
    pubmed
  • 35) Chen YN, Mickley LA, Schwartz AM, et al. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem. 1990; 265:10073-80.
    pubmed
  • 36) Ross DD, Gao Y, Yang w, et al. The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen. Cancer Res. 1997; 57:5460-4.
  • 37) Childs S, Yeh RL, Georges E, et al. Identification of a sister gene to P-glycoprotein. Cancer Res. 1995; 55:2029-34.
  • 39) Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997; 57:3537-47.
    pubmed
  • 40) Brown GA, McPherson JP, Gu L, et al. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res. 1995; 55:78-82.
    pubmed
  • 42) Friche E, Danks MK, Schmidt CA et al. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res. 1991; 51:4213-8.
    pubmed
  • 48) Tapiero H, Mishal Z, wioland M, et al. Changes in biophysical parameters and in phospholipid composition associated with resistance to doxorubicin. Anticancer Res. 1986; 6:649-52.
    pubmed
  • 50) Salinas AE, Wong MG. Glutathione S-transferases-a review. Curr Med Chem. 1999; 6:279-309.
    pubmed
  • 52) Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54:4313-20.
    pubmed
  • 54) Volm M, Mattern J. Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas. Anticancer Res. 1992; 12:2293-6.
    pubmed
  • 56) Chu E, Drake JC, Koeller DM, et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol. 1991; 39:136-43.
    pubmed
  • 57) Aszalos A Thompson K, Yin JJ, et al. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res. 1999; 19:1053-64.
  • 58) Breuninger LM, Paul S, Gaughan K et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995; 55:5342-7.
    pubmed
  • 60) Vanhoefer U, Cao S, Minderman H, et al. d, 1-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996; 2:1961-8.
  • 65) Braslawsky GR, Edson MA, Pearce w, et al. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing. Cancer Res. 1990; 50:6609-14.
  • 71) Tsuruo T, Iida H, Kitatani Y, et al. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 1984; 44:4303-7.
    pubmed
  • 76) Lopez M. Dexrazoxane. Current status and prospectives of cardiotocity of chemotherapy. Clin Ter. 1999; 150:37-49.
    pubmed
  • 77) Ermacora A, Michieli M, Pea F, et al. Liposome encapsulated daunorubicin (daunoxome) for acute leukemia. Haematologica. 2000; 85:324-5.
    pubmed
  • 79) DaunoXome shows promise as breast cancer treatment [news]. Oncology (Huntingt). 1996; 10:425.
    pubmed
  • 84) Cheung Tw, Remick SC, Azamia N, et al. AIDS-related Kaposi:s sarcoma:a phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin Cancer Res. 1999; 5:432:7.
  • 93) Hasinoff BB. Chemistry of dexrazoxane and analogues. Semin Oncol 1998; 25:3-9.
    pubmed

P.285 掲載の参考文献

  • 2) 西山正彦, 峠 哲哉. DTDとMMC. 金丸龍之介, 小西敏郎, 編, Biochemical modulationの基礎と臨床. 東京:医学書院, 1995, pp. 7582.
  • 4) Pan SS, Andrews PA, Glover CJ, et al. Reductive activation of mitomycin C and mitomycin C metabolites catalysed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem. 1984; 259:959-66.
  • 5) Hodnik WF, Sartorelli AC. Reductive activation of mitomycin Cby NADH:cytochrome b5 reductase. Cancer Res. 1993; 53:4907-12.
  • 6) Gustafson DL, Pritsos CA Enhancement of xanthine dehy-drogenase mediated mitomycin C metabolism by dicoumarol. Cancer Res. 1992; 52:6936-9.
  • 10) Waxman DJ. Glutathione-S-transferases:role in alkylating agent resistance and possible target for modulation chemo-therapy:a review. Cancer Res. 1990; 50:6442-54.
  • 12) Dorr RT. Newfindings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. Sem Oncol 1988; 15:32-41.
  • 19) Kuo MT, Bao J-J, Curly SA et al. Frequent coordinated overexpression of the MRP/GS-X pump and γ-glutamyl-cystein synthetase genes in human colorectal cancers. Cancer Res. 1992; 56:3642-4.
  • 21) Ishikawa T, Wright CD, Ishizuka H. GS-X pump functionally overexpressed in cisdiamminedichloroplatinum (II) resistant human leukemia HL-60 cells and down-regulated by cell differenciation. J Biol Chem. 1994; 269:29085-93.
  • 22) Mikami K Naito M, Tomida A.et al. DT-diaphorase as a critical deteminant of sensitivity to mitomycin C in human colon and gastric carcionoma cell lines. Cancer Res. 1996; 56:2823-6.
  • 27) O'Dwyer PJ, LaCreta F, Nash S, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res.1991; 51:6059-65.
    pubmed
  • 29) Lee JH, Naito M, Tsuruo T. Nonenzymatic reductive activation of 7-N-[2][2-8 γ-L-glutamylamino-9-ethyl] dithio] ethyl] mitomycin C by thiol molecules:anovel mitomycin C derivative effective on mitomycin C-resistant tumor cells. Cancer Res. 1994; 54:2399403.
  • 30) Xia H, Pinto T, Hu X, et al. Lack of a role of glutathione incellular nonenzymatic activation of BMS181174, a novel analogue of mitomycin C. Cancer Res. 1996; 56:34958.
  • 32) 西山正彦, 花岡奉憲, 関川高志. 抗がん剤の耐性因子の遺伝子診断-オーダー・メード療法へ. 新医療. 2000; 27:102-5.

P.292 掲載の参考文献

  • 5) 有岡仁, 西條長宏. 微小管の機能と抗癌剤. 癌と化学療法. 1994; 21:583-90.
    Medical*Online
  • 8) Lorico A, Rappa G, Flavell RA Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res. 1996; 56:5351-5.
    pubmed
  • 11) Cabral F, Sobel ME, Gottesman MM. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin. Cell. 1980; 20:29-36.
  • 14) Dumontet C, Duran GE, Steger KA, et al. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 1996; 56:1091-7.
    pubmed
  • 15) Dumontet C, Jaffrezou Jp, Tsuchiya E. Resistance to micro-tubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Elec J Oncol. 1998; 2:44-54.
  • 21) Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem. 1991; 266:3987:94.
  • 22) Haber M, Burkhart CA, Regl DL, et al. Altered expression of Mβ2, the class II beta-tubulin isotype, in a murine J774.2 cell Une with a high level of taxol resistance. J Biol Chem. 1995; 270:31269-75.
  • 23) Ranganathan S, Dexter DW, Benetatos CA Increase of beta III-and beta IVa-tubulin isotypes in human prostate carcino-ma cells as a result of estramustine resistance. Cancer Res. 1996; 56:2584-9.
  • 24) Jaffrezou JP, Dumontet C, Derry WB, et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res. 1995; 7:517-27.
    pubmed
  • 28) Liebmann JE, Hahn SM, Cook JA. Glutathione depletion by L-buthionine suifoximine antagonizes Taxol cytotoxicity. Cancer Res. 1993; 53:2066-70.
    pubmed
  • 32) Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996; 56:1253-5.
    pubmed
  • 35) Liu QY, Stein CA. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-XL and bak expression. Clin Cancer Res. 1997; 3:2039-46.
    pubmed
  • 37) Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and Adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982; 42:4730-3.
    pubmed
  • 42) Tsuruo T, Iida H, Kitatani Y, et al. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells. Cancer Res. 1984; 44:43037.
  • 43) Benson A. Trump D, Koeller J, et al. Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat Rep. 1985; 69:7959.
  • 47) Samuels BL, Hollins DR, Rosner GL, et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen:a Cancer and Leukemia Group B study. Clin Cancer Res. 1997; 3:1977-84.
  • 58) Ganapathi R, Hercbergs A Grabowski D, Ford J. Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin) [published erratum appears in Cancer Res. 1993 Dec 15; 53 (24):6079]. Cancer Res. 1993; 53:3262-5.

P.304 掲載の参考文献

  • 1) 西條長宏. 分子標的に基づく癌の治療戦略-トポイソメラーゼ阻害剤. 血液・腫瘍科. 1998; 36:8-18.
  • 4) Eng W-K Evidence that DNA topoisomerase I is necessary for cytotoxic effect of camptothecin. MolPharmacol. 1988; 34:75560.
  • 5) Hsiang YH, Hertzberg R Hecht S, liu LF, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985; 260:148738.
  • 8) Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[6-(1-piperidio)-1-piperidio]-carbonyloxycamptothecin, an novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987; 47:5944-7.
  • 11) DeVore R, et al. Phase II trial of irinotecan (CPT-11) plus cisplatin in advanced NSCLC. Proc Am Soc Clin Oncol. 1997; 16:466.
  • 13) Ten Bokkel HW, Carmichael J, Malfetano J, et al. Effcacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin Oncol. 1997; 24 (1 Supp15):19-25.
  • 14) Roman PS, Frank VF, Waun KH, et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996; 14:50313.
  • 15) Vey N, Giles FJ, Kantarjian H, et al. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin Cancer Res. 2000; 6:731-6.
  • 17) Fukuda M, Nishio K Saijo N, et al. Synergism between cisplatin and topoisomerasenl inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 1996; 56:789-93.
    pubmed
  • 19) Yoshinari T, Ohkubo M, Nishimura S, et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. 1999; 59:4271-5.
    pubmed
  • 23) Utsugi T, Shibata J, Yamada Y, et al. Antitumor activity of a novel podophyllotoxin derivative (TPO-53) against lung cancer and lung metastatic cancer. Cancer Res. 1996; 56:2809-14.
  • 27) Kanzawa F, Nishio K Saijo N, et al. Antitumor activities of a new indolcarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res. 1995; 55:2806-13.
    pubmed
  • 31) Annemarie van H, Schluper HMM, Boven E, et al. Resistance against BNP-1350 and other topoisomerase I inhibitors in variants of the human ovarian cancer cell line (abstract). Proc Am Assoc Cancer Res. 2000; 41:298.
  • 33) Beck WT, Danks MK Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Cancer Biology. 1991; 2:23544.
  • 37) 横溝晃, 谷口堅, 長谷川周二, 他. Atypical MDR. 癌と化学療法 1994; 21:1123-9.
    Medical*Online
  • 40) Danks MK Warmoth MR, Beck WT, et al. Single-strand conformation polymorphism analysis of the Mr 170, 000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res. 1993; 53:13739.
  • 41) Withoff S, De Jong S, Mulder NH, et al. Human DNA topoi:somerase II:biochemistry and role in chemotherapy resis-tance. Anticancer Res. 1996; 16:1867-80.
  • 46) Dingermans AM, Witlox MA, Giaccone G, et al. Expression of DNA topoisomerase II alpha and topoisomerase II beta genes predicts With small cell lung cancer. Clin Cancer Res. 1999; 5:2048-58.
  • 48) Harker WG, Slade DL, Parr RL, et al. Alterations in the topoisomerase IIα gene, messenger RNA and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIβ enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 1995; 55:1707-16.
  • 49) Feldhoff PW, Mirski SEL, Sullivan DM. Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung carcinoma cell Une. Cancer Res. 1994; 54:756 62.
  • 51) Sugimoto Y, Tsukahara S, Tsuruo T, et al. Decreased expression of DNA topoisomerase I in camptothecin resistant human tumor cell Unes. Cancer Res. 1990; 50:7962-5.
  • 55) Kondo H, Kanzawa F, Saijo N, et al. Analysis of in vitro combined effects of cisplatin and etoposide against small cell lung cancer cell lines. J Jpn Soc Cancer Ther. 1993; 28:592-601.
  • 58) Kojima A Hackett NR, Crystal RG. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Cancer Res. 1998; 58:4368-74.
    pubmed

P.313 掲載の参考文献

  • 2) Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 1990; 76:1704-9.
    pubmed
  • 11) Kakizuka A Miller WH Jr, Umesono K et al. Chromosomal translocation t(15; 17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell. 1991; 66:66374.
  • 12) Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t (11; 17) translocation associated with acute promyelocytic leukemia. EMBO J. 1993; 12:1161-7.
  • 14) Wells RA, Catzavelos C, Kamel-Reid S, et al. Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. 1997; 17:109-13.
  • 15) 木崎昌弘. 白血病のレチノイン酸耐性-レチノイン酸受容体とhistone deacetylase. 高久史麿, 溝口秀明, 小宮山淳, 坂田洋一, 金倉譲, 編, Annual Review血液1999, 東京:中 外医学社, 1999, p.7988.
  • 16) Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-spechic PMLRARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993; 74:42331.
  • 17) Brown D, Kogan S, Lagasse E, et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94:2551-6.
  • 18) He L-Z, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc Natl Acad Sci USA 1997; 94:5302-7.
  • 25) Hong S-H, David G, Wong C-W, et al. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α(RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94:9028-33.
  • 27) Grignani F, Matteis SD, Nervi C, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998; 391:8158.
  • 28) Guidez F, Ivins S, Zhu J, et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PMIL-and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. 1998; 91:2634-42.
  • 29) He L-Z, Guidez F, Tribioli C, et al. Distinct interactions of PMLRARα and PLZF-RARα with co-repressors detemmine differential responses to RA in APL. Nat Genet. 1998; 18:126-35.
  • 30) Delva L, Comic M, Balitrand N, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelo-cytic leukemia:study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood. 1993; 82:2175-81.
  • 36) Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-domain of RARα protein of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood. 1998; 92:374-82.
  • 37) Ding W, Li YP, Nobile LM, et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia fom treatment with all-trans retinoic acid and intensive chemotherapy. Blood. 1998; 92:1172-83.
  • 38) Kizaki M, Matsushita H, Takayama N, et al. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood. 1996; 88:1824p33.
    pubmed
  • 40) Mandelli F, Diverio D, Awisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997; 90:101421.
  • 41) Tobita T, Takeshita A Kitamura K et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood. 1997; 90:967-73.
    pubmed
  • 42) Kizaki M, Dawson MI, Heyman R, et al. Effects of novel retinoid X receptor (RXR) selective ligands on myeloid leu-kemic differentiation in vitro. Blood. 1996; 87:1977-84.
  • 44) Kizaki M, Ikeda Y, Tanosaki R, et al. Effects of novel retinoic acid compound, 9-cis retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-α and retinoid X receptor-α by HL-60 cells. Blood. 1993; 82:3592-9.
  • 49) Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide:Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94:3315-24.

P.320 掲載の参考文献

  • 1) The research group for population-based cancer registration in Japan. Cancer incidence in Japan. In:Tominaga S, et al. eds. Cancer Mortality and Morbidity Statistics. Tokyo:Karger, 1999, pp. 835.
  • 4) 島崎淳, 赤倉功一郎, 古谷雄三, 他. 抗ホルモン療法に対する抵抗性出現の機序と克服法. 抗アンドロゲン療法. 日本臨牀. 1997; 55:1143-8.
  • 5) 加藤茂明. 核内エストロゲンレセプターを介した情報伝達の分子メカニズム. 乳癌の臨床. 1998; 13:699-705.
    Medical*Online
  • 6) MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998; 50:151-96.
  • 7) Jordan VC. How does tamoxifen work? In:Jordan Vc ed. Tamoxifen for the Treatment and Prevention of Breast Cancer. Melville, NY:PRR, Inc. 1999, pp. 257-63.
  • 9) Osborne CK. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol. 1985; 12:317-26.
    pubmed
  • 10) Ottaviano YL, Issa JP, Parl FF, et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994; 54:2552-5.
    pubmed
  • 12) Karni PS, Kulkarni S, Liu X-P, et al. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994; 54:34953.
  • 15) Levenson AS, Jordan VC. The key to the antiestrogenic mechanism of raloxifen is amino acid 351 (Aspartate) in the estrogen receptor. Cancer Res. 1998; 58:1872-5.
  • 16) Speirs V, Malone C, Walton DS, et al. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999; 59:5421-4.
    pubmed
  • 17) Paech K Webb P, Kuiper GGJM, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 1997; 277:1508-10.
  • 25) Kopp A, Jonat W, Schmahl M, et al. Transfonning growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res. 1995; 55:4512-5.
    pubmed
  • 26) Gasparini G, Toi M, Miceli R, et al. Clinical relevance of vascular endothelial growth factor and thymidine phos-phorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am. 1999; 5:101-11.
    pubmed
  • 28) DiGiovanna MP. Clinical signifcance of HER-2/neu over-expression:Part I, In:Rosenberg SA, ed. Principles and Practice of Oncology Updates (Vol 13, No 9). Philadelphia, PA:Lippincott W; illiams & Willdns, 1999.
  • 39) Craft N, Chhor C, Tran C, et al. Evidence for clonal out-growth of androgen-independent prostate cancer cellsfom androgen-dependent tumors through a two-step process. Cancer Res. 1999; 59:5030-6.
  • 41) Harvey m Aromatase inhibitors in clinical practices; current status and a look to the future. Semin Oncol 1996; 23 (4 Suppl 9):338.
  • 43) 浅石和昭, 冨永健, 阿部令彦, 他. タモキシフェン療法耐 性の乳癌症例に対する高用量NK622(クエン酸トレミフェ ン)の有効性と安全性. 癌と化学療法. 1993; 20:91-9.
    Medical*Online
  • 46) Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multi-national Investigator Study Group. Semin Oncol. 1999; 26:71-7.

P.331 掲載の参考文献

  • 5) 大河内悦子, 小野謙一. 多剤耐性のメカニズムとその臨床応用-抗体を用いた診断と治療-. Molecular Medicine. 1993; 30:730-8.
  • 6) Flynn SD, Murren JR, Kirby WM, et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 1992; 112:981-6.
    pubmed
  • 7) Schinkel AH, Roelofs EM, Borst P. Characterization of the human MDR3 P-glycoprotein-specific monoclonal antibodies. Cancer Res. 1991; 51:2628-35
  • 8) Rao W, Anthony DC, Piwnica-Worms D. MDRI gene-spechic monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res. 1994; 54:1536-41.
  • 9) Kramer RA, Arceci R, Weber T, et al. Both glycosylation and phosphorylation are required for p-glycoprotein function in human colon carcinoma cells. Proc Am Assoc Cancer Res. 1992; 33:476.
  • 16) Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients:tumors:consensus recommendations. Cancer Res. 1996; 56:3010-20.
    pubmed
  • 18) Feller N, Kuiper CM, Lankelma J, et al. Functional detection of MDR1/p170 and MRP/p190-mediated multidrug resistance in tumour cells by flow cytometry, Br J Cancer. 1995; 72:5439.
  • 19) 河端正樹, 小林広幸, 森茂久, 他. ローダミン123色素排泄能測定による白血病細胞のP糖蛋白機能発現の解析. 臨床病理. 1997; 45:891-8.
    Medical*Online
  • 21) Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992; 80:27359.
  • 22) 西川潔, 宮崎年恭, 塚口信彦, 他. CD45抗体を併用した急性白血病細胞表面マーカー分析の精度向上の試み. 臨床病理. 1996; 44:548-53.
    Medical*Online
  • 25) Noonan KE, Beck C, Hoizmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87:71604.
  • 26) Ostrowski LE, Krieg P, Finch J, et al. Expression of β-actin during Progression of mouse skin tumors. Carcinogenesis. 1989; 10:1439-44.
  • 35) Siebert PD, Larrick JW. PCR MIMICs:Competitive DNA fragments for use as intemal standards in quantitative PCR. Bio Techniques. 1993; 14:2449.
  • 36) 小林広幸, 竹村譲. 造血器腫瘍細胞における多剤耐性形質の定量的検出法. 臨床病理. 1998; 46:380-90.
    Medical*Online
  • 37) Chen CJ, Clark D, Ueda K, et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem. 1990; 265:50614.
  • 39) Arkin H, Ohnuma T, Kamen BA, et al. Multidrug resistance in ahuman leukemic cell line selected for resistance to trime-trexate. Cancer Res. 1989; 49:655661.
  • 42) Gema G, Baldanti F, Lilleri D, et al. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients. J Clin Micro-biol 2000; 38:184553.
  • 43) Brophy NA, Marie JP, Rojas VA, et al. Mdrl gene expression in childhood acute lymphoblastic leukemias and lymphomas:acritical evaluation by four techniques, Leukemia. 1994; 8:327-35.
  • 45) Arceci RJ. Clinical significance of P:glycoprotein in multidrug resistance malignancies. Blood. 1993; 81:221522.
  • 47) List AF. Multidrug resistance:clinical relevance ln acute leukemia. Oncology (Huntingt). 1993; 7:23-28.
  • 58) Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias:correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991; 78:586-92.
    pubmed
  • 64) Miyachi H, Takemura Y, Yonekura S, et al. MDR1 (multidrug resistance) gene expression in adult acute leukemia; correlations with blast phenotype. Int J Hematol. 1993; 57:31-7.
    pubmed
  • ●中内啓光監修.(細胞工学別冊)フローサイトメトリー自由自在. 秀潤社, 1998.
  • ●野地澄晴編(別冊実験医学 ザ・プロトコールシリーズ)免疫染色・in situハイブリダイゼーション. 羊土社, 1997.
  • ●塩原正明.ウエスタン解析.(血液腫瘍科 第40巻特別増刊号)臨床血液実験操作法. 科学評論社, 1998, pp.112-20.
  • ●関哲則.RNAの分析. ドットプロット.小池克郎, 関谷剛男, 近藤寿人編. 分子生物学プロトコール. 南江堂, 1994, P.60.
  • ●野地澄晴編(別冊実験医学 ザ・プロトコールシリーズ)免疫染色・in situハイブリダイゼーション. 羊土社, 1997.
  • ●酒井正春. ノーザンプロット法, 村松正實, 山本雅 編 (実験医学別冊)新遺伝子工学ハンドブック(改訂第3版). 羊土社, 1999, pp.86-90.
  • ●西本正純. RNaseプロテクションアッセイ. 村松正實, 山本雅編. (実験医学別冊)新遺伝子工学ハンドブック(改訂第3版). 羊土社, 1999, pp.103-6.
  • ●木下朝博. PCR法によるRNA検出・定量のストラティジー. 矢崎義雄監修. PCR法 利用の手引き. 中外医学社, 1998. pp.68-78.
  • ●小林優, 川口竜二.NASBA法によるキメラ遺伝子の検出(血液腫瘍科第40巻特別増刊号)臨床血液実験操作法. 科学評論社, 1998, pp.423-30.
  • ●辻本豪三, 田中利男編.(実験医学別冊)ゲノム機能研究プロトコール.マイクロアレイ, PCR, バイオインフォマティクスの最新技術からSNP, モデル生物の解析まで. 羊土社, 2000.

P.341 掲載の参考文献

  • 1) Ratain MJ. Pharmacology of cancer chemotherapy. In:DeVita VT Jr, et al. eds. Cancer:Principles & Practice of Oncology. Fifth ed. Philadelphia:Lippincott-Raven Pub, 1997, pp. 375-85.
  • 3) Goldie JH. Drug resistance. In:Perry MC, ed. The Chemotherapy Source Book. 2nd ed. Baltimore:Williams & Wilkins, 1996, pp. 63-78.
  • 4) Kaufman D, Chabner BA Clinical strategies for cancer treatment:the role of Drugs. In:Chabner BA, et al. eds. Cancer Chemotherapy and Biotherapy:Principles and Practice, 2nd ed, Philadelphia:Lippincott-Raven Pub, 1996, pp. 1-16.
  • 5) 竹村 譲, 宮地勇人. 抗腫瘍剤に対する薬剤感受性・耐性検出検査. Lab Clin Pract.1992; 10:24-9.
  • 6) 宮地勇人, 小林広幸, 竹村 譲. 多剤耐性の遺伝子検査.臨床検査. 1997; 41:283-9.
  • 7) 竹村 譲, 小林広幸, 宮地勇人. 癌の多剤耐性形質とその検出方法. 臨床病理. 1998; 46:74558.
  • 8) Boddy AV, Idle JR. The role of pharrnacogenetics in chemotherapy:modulation of tumour response and host toxicity. Cancer Surv. 1993; 17:79-104.
    pubmed
  • 12) Houghton PJ, Kaye SB. Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. JNIH Res. 1994; 6:55.
  • 13) Zaman GJ, Versantvoort CH, Smit JJ, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993; 53:1747-50.
    pubmed
  • 15) Morrow CS, Cowan KH. Glutathione Stransferases and drug resistance. Cancer Cells. 1990; 2:1522.
  • 18) Allikmets R, Schriml LM, Hutchinson A et al. A human placenta-specific ATP-bindmg cassette gene (ABCP) on chromosome 4q22 that is invoived in multidrug resistance. Cancer Res. 1998; 58:5337-9.
  • 19) Ramachandran C, You W, Krishan A Characterization of a novel drug resistance-associated protein (DRP). Proc AACR. 1998; 39:557.
  • 20) 宮地勇人. 白血病の遺伝子異常. 臨床病理臨時増刊特集第 97号; 検査血液学. 臨床病理学会編, 東京:臨床病理刊行会, 1994, pp. 174-9.
  • 21) Hamlin JL. Drug resistance:DNA sequence amplification. In:Bertino JR, ed. Encyclopedia of Cancer, San Diego:Academic Press lnc, 1997, pp. 772-82.
  • 27) Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem. 1994; 54:440-52.
    pubmed
  • 29) Takemura Y, Kobayashi H, Miyachi H. Cellular and molecular mechanisms of resistance to antifolate drugs:new analogues and approaches to overcome the resistance. Int J Hematol. 1997; 66:45977.
  • 33) Krett NL, Pillay S, Moalli PA, et al. A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. Cancer Res. 1995; 55:2727-9.
    pubmed
  • 34) Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995; 55:1407-12.
    pubmed
  • 39) Zuhlsdorf MT. Relevance of pheno-and genotyping in clinicaldrug development Int J Clin Pharmacol Ther. 1998; 36:607-12.
  • 40) Gonzalez FI, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Phar-macokinet. 1994; 26:59-70.
  • 50) Lohri A, van Hille B, Bacchi M, et al. Five putative drugresistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-Stransferase, bcl-2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias. Eur J Haematol. 1997; 59:206-15.
  • 51) Miyachi H, Han H, Scanlon KI. Dihydrofolate reductase gene expression characterized by the PCR assay in human leukemia cells. In Vivo. 1991; 5:7-12.
  • 52) Flens MJ, Zaman GJ, vander Valk P, et al. Tissue distribution of the multidmg resistance protein. Am J Pathol. 1996; 148:1237-47.
  • 54) Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribu-tion of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J pathol. 1996; 148:877-87.
  • 55) Miyachi H, Takemura Y, Yonekura S, et al. MDR1 (multidrug resistance) gene expression in adult acute leukemia:correla-tions With blast phenotype. Int J Hematol. 1993; 57:31-7.
  • 56) 宮地勇人. 造血器腫瘍の遺伝子検査における精度管理. 臨床 病理. 2000; 48:892-9.
    Medical*Online
  • 59) 宮地勇人. 自動化システムによる遺伝子検査. 臨床病理. 1998; 46:4139.
  • 60) 舩渡忠男, 佐藤淳子, 佐々木毅. 定量的PCRシステムの臨床応用. 臨床病理. 1998; 46:399-405.
    Medical*Online
  • 62) 宮地勇人, 竹村譲, 安藤泰彦. 白血病細胞における葉酸誘導体耐性のPCR法による検出. 臨床病理. 1993; 41:77984.
  • 63) Lianidou ES, Levesque MA, Katsaros D, et al. Immuno-fluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Res. 1999; 19:749-56.
  • 71) Beck J, Handgretinger R, Klingebiel T, et al. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia. 1996; 10:426-33.
    pubmed
  • 73) Hart SM, Ganeshaguru K, Scheper RJ, et al. Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol. 1997; 25:1227-32.
    pubmed
  • 77) Goker E, Waltham M, Kheradpour A et al. Amplification of the dihydrofblate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lympho-blastic leukemia and is correlated with p53 gene mutations. Blood. 1995; 86:677-84.
  • 78) Morabito F, Filangeri M, Callea I, et al. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia:correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica. 1997; 82:16-20.
    pubmed
  • 82) Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Phamacokinet. 1997; 32:32443.
  • 88) Taniguchi K, Wada M, Kohno K et al. A human canahcular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell hnes with decreased drug accumulation. Cancer Res. 1996; 56:41249.
  • ●サザン法. ゲノム解析ラボマニュアル. 中村祐輔編. 東京:シュプリンガー・フェアラーク東京, 1998, pp.2530.
  • ●関谷剛男, SSCP法. PCR法最前線. 関谷剛男, 他編. 東京:共立出版, 1997, pp.133-9.
  • ●永瀬 智, 堀井 明. PCR-RFLP法. PCR法最前線. 関谷剛男, 他編. 東京:共立出版, 1997, pp.158-61.
  • ●斎藤昌枝, 服部正平. PCRと塩基配列決定. PCR法最前線. 関谷剛男, 他編. 東京:共立出版, 1997, pp.116-24.
  • ●磯野一宏. 蛍光色素による定量的PCR. non-RI実験の最新プロトコール. 栗原靖之, 他編. 東京:羊土社, 1999, pp.83-9.
  • ●関直彦, 永杉友美, 東 孝典, 他. cDNAマイクロアレイによる分化誘導遺伝子の検出, ゲノム機能研究プロトコール. 辻本豪三, 田中利男, 他編. 東京:羊土社, 2000, pp.33-48.
  • ●渡辺真哉. DNAマイクロアレイの作製法と使用法. 細胞工学. 18;1999, pp.728-734.

P.355 掲載の参考文献

  • 5) Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC haif-transporter, MXR. J Cell Sci. 2000; 113:2011-21.
  • 8) Rao VV, Anthony DC, Piwnica-Worms D. MDRI gene-specific monoclonal antibody C494 cross-reacts with pyruvate car-boxylase. Cancer Res. 1994; 54:1536-41.
  • 11) Lathan B, Edwards DP, Dressler LG, et al. Immunological detection of Chinese hamster ovary cens expressing a multi-drug resistance phenotype. Cancer Res. 1985; 45:50649.
  • 12) Robert JA, Kimberly S, Johannes B, et al. Monoclonal anti-body to an extemal epitope of the human mtdr-1 P-glycoprotein. Cancer Res. 1993; 53:310-7.
  • 15) Yanovich S, Hall RE, Gewirtz DA. Characterization of a K562 multidrug-resistant cell line. Cancer Res. 1989; 49:449{) 503.
  • 16) Danks MK Metzger DW, Ashmun RA, et al. Monoclonal antibodies to glycoproteins of vinca alkaloid-resistant human leukemic cells. Cancer Res. 1985; 45:32204.
  • 18) Flens MJ, Izquierdo MA Scheffer GL, et al. Immunochemical detection of the mulddrug-resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994; 54:4557-63.
    pubmed
  • 19) List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996; 87:2464-9.
    pubmed
  • 24) Hu XF, Slater A, Kantharidis P, et al. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood. 1999; 93:408 (}95.
  • 29) Lehne G, Rugstad HE. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukemia cells with increased expression of P-glycoprotein. Br J Cancer. 1998; 78:593600.
  • 34) Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54:431320.
  • 38) Tidefelt U, Elmhom-Rosenborg A, Paul C, et al. Expression of glutathione transferase as a predictor fbr treatment results at different stages of acute nonlymphoblastic leukemia. Cancer Res. 1992; 52:3281-5.
  • 40) Yamane Y, Furuichi M, Song R, et al. Expression of multidrug resistance protein/GS-X pump andγ-glutamylcysteine syn-thetase genes is regulated by oxidative stress. J Biol Chem. 1998; 273:31075-85.
  • 44) 井上勝一. 染色法. 河本圭司, 井上勝一, 中内啓光, 他編. 応用サイトメトリー, 東京:医学書院, 2000, pp. 178-84.
  • 46) Rice GC, Bump EA, Shrieve DC, et al. Quantitative analysis of cellular glutathione by flow cytometry utilizing monochlo-robimane:some applications to radiation and drug resistance in vitro and in vivo. Cancer Res. 1986; 46:610510.
  • 51) De Jong S, Zijlstra JG, de Vries EGE, et al. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1990; 50:304-9.
  • 52) Feldhoff PW, Mirski SE, Cole SP, et al. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res. 1994; 54:75662.
  • 55) Chen M, Beck WT. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, dis-play no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. 1993; 53:5946-53.
  • 58) Dolan ME, McRae BL, Ferries-Rowe E, et al. 06-alkylguanine DNA alkyltransferase in cutaneous T-cell lymphoma:implications for treatment with alkylating agents. Clin Cancer Res. 1999; 5:2059-64.
  • 59) Frankfurt OS, Seckinger D, Sugarbaker EV. Flow cytometric analysis of DNA damage and repair in the cells resistant to alkylating agents. Cancer Res. 1990; 50:44537.
  • 63) Marra G, Chang CL Laghi LA, et al. Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferat-ing cells. Oncogene. 1996; 13:218996.
  • 66) Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51:6304-11.
    pubmed
  • 75) 中村幸夫. アポトーシス. 河本圭司, 井上勝一, 中内啓光, 他編応用サイトメトリー, 東京:医学書院, 2000, pp.82-5.
  • ●Robinson JP, Darzynkiewicz Z, Dean P, et al. eds. Current Protocols in Cytometry, New York:John Wiley & Sons
  • ●河本圭司, 井上勝一, 中内啓光, 編. 応用サイトメトリー, 東京:医学書院,2000,pp.369.
  • ●杉下匡, 高本滋, 中原一彦, 野村和弘, 編. フローサイトメトリー入門, 東京:トプコ,1993, pp.100.
  • ●中原一彦, 編 フローサイトメトリー-最近の進歩. 臨床検査.1997;41:1101-72.

P.364 掲載の参考文献

  • 4) Maloney DG, Grillo-Lopez AJ, White CA et al. IDECC2BB (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non Hodgkin's lymphoma. Blood. 1997; 90:2188-95.
    pubmed
  • 8) Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-spechic idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood. 1997; 89:3129-35.
    pubmed
  • 14) Dees EC, O'Reilly S, Figg WD, et al. A phase I and phmara-cologic study of UCN-01, a protein kinase C inhibitor. (Abstr 797) Proc Am Soc Clin Oncol. 2000; 19:205a.
  • 21) Schwartz GK, Kaubisch A. Saltz L,et al. Phase I trial of sequential paclitaxel and the cycolin dependent kinase inhibitor flavopiridol. (abstr 614) Proc Am Soc Clin Oncol. 2000; 19:160a.
  • 32) Ask A. Persson L, Rehnholm A, et al. Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylomithine as a result of coamplification of genes for ornithine decar-boxylase and ribonucleotide reductase R2 subunit. Cancer Res. 1993; 53:5262-8.
  • 38) Duan Z, Feller AJ, Penson RT, et al. Discovery of diffrentially expressed genes associated with paclitaxel resistance using cDNA array technology:analysis of interleukin (IL) 6, IL8, and monocyte chemotactic protein 1 in the pachtaxel-resistant phenotype. Clin Cancer Res. 1999; 5:3445-53.
  • 42) Paweletz CP, Orenstein DK Gillespie JW, et al. A novel, proteomic approach to monitor carcinogenic disease pro-gression using surface enhanced desorption inonization spectroscopy (SELDI) of laser capture microdissection (LMD)-derived cells from cancer tissue. (Abstr 2717) Proc Am Assoc Cancer Res. 1999; 40:411.
  • 46) Moscow JA, Huang H, Carter C, et al. Engraftment of MDRl and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood, 1999; 94:52-61.
  • 48) Parker VP, Sandbeg JA Smith J, et al. Phase 1 and pharmacokinetic studies of Angiozyme, a synthetic ribozyme targeting the VEGF receptor Flt-1. (Abstr 703) Proc Am Soc Clin Oncol. 2000; 19:181a.
  • 49) Jameson MB, Thompson PI, Baguley BC, et al. Phase I pharmacokinetic and phamacodynatic study of 5, 6 Dimethylxanthenone-4-acetic acid (DMXAA) anovel anti-vascular agent. (abstr 705) Proc Am Soc Clin Oncol. 2000; 19:182a.
  • 50) Eskens F, Dumez J, Vermeij J, et al. Phase I and pharma-colgic study of EMD 121974, an αvβ3 and αvβ5 integrin inhibitor that perturbs tumor angiogenesis, in patietns with solid tumors. (abst 801) Proc Am Soc Cnn Oncol. 2000; 19:206a.
  • 53) Fong TA Shawer LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999; 59:99-106.
  • 54) Laird D, Carver J, Smith K, et al. SU6668, a broad spec-trum angiogenesis inhibitor, exhibits potent activity against established tumors in diverse mouse xenograft models. (Abstr 3615) Proc Am Assoc Cancer Res. 2000; 41:567.
  • 55) Kahdas M, Hammond LA, Patnaik A et al. A Phase I and pharmacokinetic study of the angiogenesis inhibitor, Sequalamine lactate (MS1-1256). (abstr 698) Proc Am Soc Clin Oncol. 2000; 19:180a.
  • 57) Yarchoan R. Therapy fbr Kaposi's sarcoma:recent advances and experimental approaches. J Acquir Immune Defic Syndr. 1999; 21 (Suppl 1):S66-73.
  • 58) Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol. 1999; 26 (4Suppl 12):71-7.
  • 60) Figg WD, Cole KA, Reed E, et al. Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction. Clin Cancer Res. 1995; 1:797-803.
    pubmed
  • 62) Cassidy J, Twelves C, Bissett D, et al. Phase I clinical and phamlacokinetic study of the novel cell cycle inhibitor Ro 31-7453. (Abstr. 731) Proc Am Soc Clin Oncol. 2000; 19:188a.
  • 63) Slack JL, Gallagher RE. The molecular biology of acute promyelocytic leukemia. Cancer Treat Res. 1999; 99:75124.
  • 64) Rizvi NA Marshall JL, Dahut W, et al. A Phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res. 1999; 5:1658-64.
    pubmed
  • 65) Andreeff M, Stone R, Michaeli J, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelo-genous leukemia:a phase II clinical trial with a diffrentiation-inducing agent. Blood. 1992; 80:2604-9.
  • 66) Siu LL, Gelmon KA, Moore MFJ, et al. A phase I and pharmacokinetic study of the human methyltransferase antisense oligodeoxynucleotide G98 given as a 21-day continuous infu sion every 4 weeks. (Abstr 733) Proc Am Soc Clin Oncol. 2000; 19:189a.
  • 67) Ryan DP, Eder Jp, Supko JG, et al. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 in patients with advanced solid tumors. (Abstr 720) Proc Am Soc Clin Oncol. 2000; 19:185a.
  • 68) Soignet S, Yao S-L, Britten C, et al. Pharmacokinetics and pharmaodynamics of the farnesyl protein transferase inhibitor (L778, 123) in solid tumors. (Abstr 3412) Proc Am Assoc Cancer Res. 1999; 40:517.
  • 70) Adjei AA, Erlichman C, Davis JN, et al. A phase I and pharmacologic study of the farnesyl protein transferase inhibitor SCH 66336 in patients with locally advanced or metastatic cancer. (Abstr 598) Proc Am Soc Clin Oncol. 1999; 18:156a.
  • 74) Malingre MM, ten Bokkel Huinink WW, Paul EM, et al. Co-administration of the MDR modulator GF120918 results in significant systemic exposure to oral paclitaxel. (Abstr 721) Proc Am Soc Clin Oncol. 2000; 19:186a.
  • 75) Rubin E, Zamek R, Medina M, et al. A phase I trial of LY335979, a potent multi drug-resistance modulator, administered orally in combination with doxrubicin. (Abstr 705) Proc Am Soc Clin Oncol. 1999; 18:183a.
  • 77) Ranson M, Cheeseman S, McGown A, et al. Phase I trial of CT2584HMS, a modulator of phosphatidic acid in patient with advanced solid tumours. (Abstr 613) Proc Am Soc Clin Oncol. 1999; 18:159a.
  • 78) Chen HX, Marshall JL, Ness E, et al. A safety and pharmacokinetic study of a mixed-backboone oligonucleotide (GEM231) targeting the type 1 protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res. 2000; 6:125966.
  • 79) Varterasian ML, Mohammad RM, Shurafa MS, et al. Phase II trial of bryostatin I in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2000; 6:825-8.
    pubmed
  • 80) Sikic BI, Yuen A, Advani R, et al. A phase I trial of ISIS 3521 (ISI 641A), an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients With cancer. (Abstr 1718) Proc Am Soc Clin Oncol. 1999; 18:445a.
  • 81) Anthoney A, Paz-Ares L, Twelves C, et al. Phase I and pharmacokinetic study of aplidine using a 24-hour, weekly schedule. (Abstr 734) Proc Am Soc Clin Oncol. 2000; 19:189a.
  • 82) Aghajanian C, Elliott P, Adams J, et al. Phase I trial of the proteasome inhibitor PS-341 in advanced malignancy. (Abstr 736) Proc Am Soc Clin Oncol. 2000; 19:189a.
  • 83) Marshall J, Bhargava P, Kindler H, et al. Phase I study of oral CEP-701, a novel neurotrophin receptor-linked TK inhibitor. (Abstr 713) Proc Am Soc Clin Oncol. 2000; 19:184a.
  • 84) O'Dwyer PJ, Stevenson Jp, Gallagher M, et al. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res. 1999; 5:3977-82.
  • 85) Holmlund JT, Rudin CM, Mani S, et al. Phase I trial of ISIS 5132/ODN 698A, a 20-mer phosphorothioate antisense oligonucleotide inhibitor of C-RAF kinase, administered by a24-hour weekly intravenous infusion to patients with advanced cancer. (Abstr 605) Proc Am Soc Clin Oncol. 1999; 18:157a.
  • 86) Rosen L Hannah A. Rosen P, et al. Phase I dose-escalatiing trial of oral SU006668, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies. (Abstr 708) Proc Am Soc Clin Oncol. 2000; 19:182a.
  • 87) Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (lressa), anovel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five seected tumor tyes:evidence of activity and good tolerability. (Abstr 686) Proc Am Soc Clin Oncol. 2000; 19:177a.
はじめての方へ
個人／法人会員登録のご案内